[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 372
1. Huang Y, Wang X, Cui Z, Yang Y, Xiao Y, Tang L, Kan B, Xu J, Jing H: Possible use of ail and foxA polymorphisms for detecting pathogenic Yersinia enterocolitica. BMC Microbiol; 2010;10:211

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible use of ail and foxA polymorphisms for detecting pathogenic Yersinia enterocolitica.
  • BACKGROUND: Yersinia enterocolitica is an enteric pathogen that invades the intestinal mucosa and proliferates within the lymphoid follicles (Peyer's patches).
  • The attachment invasion locus (ail) mediates invasion by Y. enterocolitica and confers an invasive phenotype upon non-invasive E. coli; ail is the primary virulence factor of Y. enterocolitica.
  • Currently, ail is the primary target gene for nucleic acid detection of pathogenic Y. enterocolitica.
  • RESULTS: The genes ail and foxA in 271 pathogenic and 27 non-pathogenic Y. enterocolitica strains isolated from China and 10 reference strains were sequenced, aligned, compared to the ail and foxA sequences of Yersinia enterocolitica subsp. enterocolitica 8081 (Genbank: NC_008800), and analyzed for sequence polymorphism.
  • The ail from the 282 strains showed 3 sequence patterns: 277 strains of serotypes O:3, O:9 and O:5, 27 with identical nucleic acid sequences formed pattern A1; 4 strains of serotype 1B/O:8 with identical nucleic acid sequences formed pattern A2; and one Chinese isolate 2/O:9 formed pattern A3.
  • CONCLUSION: The ail and foxA loci of pathogenic Y. enterocolitica have been analyzed.
  • The ail sequence was highly conserved among the same serotype strains from different sources; and foxA was highly conserved among the pathogenic strains, although there was some sequence diversity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 1998 May;180(9):2579-82 [9573216.001]
  • [Cites] J Am Chem Soc. 2005 Feb 2;127(4):1137-45 [15669853.001]
  • [Cites] Jpn J Infect Dis. 2005 Feb;58(1):31-3 [15728988.001]
  • [Cites] Int J Food Microbiol. 2008 Jul 31;125(3):259-66 [18541322.001]
  • [Cites] Appl Environ Microbiol. 2008 Oct;74(19):6060-7 [18708521.001]
  • [Cites] Zentralbl Bakteriol. 1993 Apr;278(2-3):416-24 [8347944.001]
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):3750-5 [10966386.001]
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):4131-5 [10966441.001]
  • [Cites] J Food Prot. 2001 Sep;64(9):1352-61 [11563512.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Feb;4(2):105-16 [12563288.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1810-6 [12620874.001]
  • [Cites] J Med Microbiol. 2004 Nov;53(Pt 11):1065-8 [15496381.001]
  • [Cites] Infect Immun. 1975 Jan;11(1):164-70 [1116874.001]
  • [Cites] CRC Crit Rev Microbiol. 1977;5(2):211-41 [844324.001]
  • [Cites] J Bacteriol. 1979 Mar;137(3):1290-8 [108243.001]
  • [Cites] Annu Rev Microbiol. 1982;36:435-65 [6756294.001]
  • [Cites] Infect Immun. 1984 Oct;46(1):105-10 [6480101.001]
  • [Cites] J Med Microbiol. 1985 Apr;19(2):237-46 [3981611.001]
  • [Cites] J Bacteriol. 1987 Jun;169(6):2624-30 [3294800.001]
  • [Cites] Biochemistry. 1987 Aug 25;26(17):5471-7 [2823881.001]
  • [Cites] Infect Immun. 1989 Jan;57(1):121-31 [2642465.001]
  • [Cites] N Engl J Med. 1989 Jul 6;321(1):16-24 [2659991.001]
  • [Cites] J Bacteriol. 1990 Feb;172(2):1062-9 [1688838.001]
  • [Cites] Infect Immun. 1990 Apr;58(4):1059-64 [1690684.001]
  • [Cites] Gut. 1990 Sep;31(9):1011-5 [2210445.001]
  • [Cites] J Bacteriol. 1991 Jan;173(2):417-25 [1898928.001]
  • [Cites] J Bacteriol. 1992 Feb;174(3):1029-35 [1732192.001]
  • [Cites] Mol Microbiol. 1992 May;6(10):1309-21 [1640832.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Mol Microbiol. 1993 Apr;8(2):397-408 [8316088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6473-7 [8341658.001]
  • [Cites] Clin Microbiol Rev. 1997 Apr;10(2):257-76 [9105754.001]
  • [Cites] Mol Microbiol. 1997 Nov;26(4):799-808 [9427409.001]
  • [Cites] J Bacteriol. 1998 Feb;180(3):538-46 [9457855.001]
  • (PMID = 20691098.001).
  • [ISSN] 1471-2180
  • [Journal-full-title] BMC microbiology
  • [ISO-abbreviation] BMC Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / FoxA protein, bacteria; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ PMC2924855
  •  go-up   go-down


2. Tsang TM, Felek S, Krukonis ES: Ail binding to fibronectin facilitates Yersinia pestis binding to host cells and Yop delivery. Infect Immun; 2010 Aug;78(8):3358-68
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ail binding to fibronectin facilitates Yersinia pestis binding to host cells and Yop delivery.
  • Yersinia pestis, the causative agent of plague, evades host immune responses and rapidly causes disease.
  • The Y. pestis adhesin Ail mediates host cell binding and is critical for Yop delivery.
  • To identify the Ail receptor(s), Ail was purified following overexpression in Escherichia coli.
  • Ail bound specifically to fibronectin, an extracellular matrix protein with the potential to act as a bridge between Ail and host cells.
  • Ail expressed by E. coli also mediated binding to purified fibronectin, and Ail-mediated E. coli adhesion to host cells was dependent on fibronectin.
  • Ail expressed by Y. pestis bound purified fibronectin, as did the Y. pestis adhesin plasminogen activator (Pla).
  • However, a KIM5 Delta ail mutant had decreased binding to host cells, while a KIM5 Delta pla mutant had no significant defect in adhesion.
  • Furthermore, treatment with antifibronectin antibodies decreased Ail-mediated adhesion by KIM5 and the KIM5 Delta pla mutant, indicating that the Ail-fibronectin interaction was important for cell binding.
  • Finally, antifibronectin antibodies inhibited the KIM5-mediated cytotoxicity of host cells in an Ail-dependent fashion.
  • These data indicate that Ail is a key adhesin that mediates binding to host cells through interaction with fibronectin on the surface of host cells, and this interaction is important for Yop delivery by Y. pestis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):241-53 [9531562.001]
  • [Cites] Infect Immun. 1998 Sep;66(9):4545-8 [9712817.001]
  • [Cites] Infect Immun. 1998 Dec;66(12):5755-62 [9826351.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52 [9841674.001]
  • [Cites] Microbiology. 2008 Jun;154(Pt 6):1802-12 [18524935.001]
  • [Cites] PLoS Pathog. 2008;4(8):e1000140 [18769718.001]
  • [Cites] Infect Immun. 2009 Feb;77(2):825-36 [19064637.001]
  • [Cites] Microbiology. 2009 Feb;155(Pt 2):498-512 [19202098.001]
  • [Cites] Infect Immun. 1988 May;56(5):1242-8 [2833444.001]
  • [Cites] Nature. 1988 Aug 11;334(6182):522-4 [3043229.001]
  • [Cites] Mol Microbiol. 1989 Mar;3(3):329-37 [2568575.001]
  • [Cites] Matrix Biol. 1999 Jun;18(3):211-23 [10429941.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1920-3 [10489373.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17837-42 [15598742.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3375-80 [16488979.001]
  • [Cites] FEMS Microbiol Lett. 2006 Sep;262(2):158-62 [16923070.001]
  • [Cites] Microbes Infect. 2006 Jul;8(8):2291-8 [16782385.001]
  • [Cites] Infect Immun. 2007 Mar;75(3):1272-9 [17178780.001]
  • [Cites] Structure. 1999 Oct 15;7(10):1301-9 [10545325.001]
  • [Cites] Mol Microbiol. 2000 Aug;37(3):515-27 [10931345.001]
  • [Cites] Eur J Cell Biol. 2000 Oct;79(10):659-71 [11089914.001]
  • [Cites] FEBS Lett. 2001 Aug 24;504(1-2):69-72 [11522299.001]
  • [Cites] FEBS Lett. 2001 Aug 31;504(3):173-8 [11532450.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(5):1053-62 [11555286.001]
  • [Cites] Nature. 2001 Oct 4;413(6855):523-7 [11586360.001]
  • [Cites] Infect Immun. 2002 Sep;70(9):4880-91 [12183532.001]
  • [Cites] J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3 [12244123.001]
  • [Cites] Microb Pathog. 2002 Dec;33(6):265-77 [12495673.001]
  • [Cites] J Lipid Res. 2003 Feb;44(2):320-30 [12576514.001]
  • [Cites] Curr Opin Infect Dis. 2003 Jun;16(3):225-9 [12821812.001]
  • [Cites] J Clin Invest. 1977 Oct;60(4):855-65 [19499.001]
  • [Cites] Int J Cancer. 1977 Jul 15;20(1):1-5 [903179.001]
  • [Cites] FEBS Lett. 1979 Jan 15;97(2):221-4 [761627.001]
  • [Cites] Science. 1980 Aug 22;209(4459):927-9 [7403857.001]
  • [Cites] Cell. 1981 Oct;26(2 Pt 2):259-67 [6174240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jan;80(1):137-41 [6218503.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(11):3471-5 [6374658.001]
  • [Cites] J Biol Chem. 1985 Apr 10;260(7):4492-500 [3920218.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Adv Exp Med Biol. 2007;603:97-105 [17966407.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] PLoS Pathog. 2008 Jan;4(1):e3 [18193942.001]
  • [Cites] Cell. 1990 Mar 9;60(5):861-71 [2311122.001]
  • [Cites] Mol Microbiol. 1990 Apr;4(4):657-67 [2191183.001]
  • [Cites] Infect Immun. 1990 Aug;58(8):2569-77 [2164509.001]
  • [Cites] Methods Enzymol. 1990;185:60-89 [2199796.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):156-60 [1987115.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):86-93 [1846140.001]
  • [Cites] Gene. 1991 Jan 2;97(1):39-47 [1847347.001]
  • [Cites] J Biol Chem. 1991 Jul 15;266(20):12840-3 [1677003.001]
  • [Cites] J Bacteriol. 1991 Sep;173(17):5298-307 [1679429.001]
  • [Cites] Mol Microbiol. 1991 Jun;5(6):1439-45 [1686292.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] Mol Microbiol. 1991 Dec;5(12):3063-72 [1809845.001]
  • [Cites] Infect Immun. 1992 Jul;60(7):3021-4 [1612772.001]
  • [Cites] J Gen Microbiol. 1992 Aug;138 Pt 8:1679-87 [1527508.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Annu Rev Microbiol. 1994;48:585-617 [7826020.001]
  • [Cites] J Bacteriol. 1995 Feb;177(3):799-804 [7836315.001]
  • [Cites] J Bacteriol. 1995 Oct;177(20):5997-6000 [7592356.001]
  • [Cites] Infect Immun. 1996 Jan;64(1):375-9 [8557370.001]
  • [Cites] EMBO J. 1996 Mar 1;15(5):989-98 [8605894.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2483-9 [8698470.001]
  • [Cites] Science. 1996 Aug 30;273(5279):1231-3 [8703058.001]
  • [Cites] FEMS Immunol Med Microbiol. 1996 May;14(1):53-7 [8804976.001]
  • [Cites] Mol Microbiol. 1997 May;24(3):499-510 [9179844.001]
  • [Cites] Mol Microbiol. 1997 Jun;24(5):953-63 [9220003.001]
  • [Cites] Mol Microbiol. 1998 Mar;27(5):953-65 [9535085.001]
  • (PMID = 20498264.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / Fibronectins; 0 / Recombinant Proteins; 0 / Virulence Factors
  • [Other-IDs] NLM/ PMC2916272
  •  go-up   go-down


3. Bartra SS, Styer KL, O'Bryant DM, Nilles ML, Hinnebusch BJ, Aballay A, Plano GV: Resistance of Yersinia pestis to complement-dependent killing is mediated by the Ail outer membrane protein. Infect Immun; 2008 Feb;76(2):612-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of Yersinia pestis to complement-dependent killing is mediated by the Ail outer membrane protein.
  • Yersinia pestis, the causative agent of plague, must survive in blood in order to cause disease and to be transmitted from host to host by fleas.
  • Members of the Ail/Lom family of outer membrane proteins provide protection from complement-dependent killing for a number of pathogenic bacteria.
  • The Y. pestis KIM genome is predicted to encode four Ail/Lom family proteins. Y. pestis mutants specifically deficient in expression of each of these proteins were constructed using lambda Red-mediated recombination.
  • The Ail outer membrane protein was essential for Y. pestis to resist complement-mediated killing at 26 and 37 degrees C.
  • Ail was expressed at high levels at both 26 and 37 degrees C, but not at 6 degrees C.
  • Expression of Ail in Escherichia coli provided protection from the bactericidal activity of complement.
  • High-level expression of the three other Y. pestis Ail/Lom family proteins (the y1682, y2034, and y2446 proteins) provided no protection against complement-mediated bacterial killing.
  • A Y. pestis ail deletion mutant was rapidly killed by sera obtained from all mammals tested except mouse serum.
  • The role of Ail in infection of mice, Caenorhabditis elegans, and fleas was investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5 [10829079.001]
  • [Cites] Structure. 1999 Oct 15;7(10):1301-9 [10545325.001]
  • [Cites] Am J Trop Med Hyg. 2000 May;62(5):552-60 [11289663.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(5):1053-62 [11555286.001]
  • [Cites] Nature. 2001 Oct 4;413(6855):523-7 [11586360.001]
  • [Cites] Nature. 2002 May 16;417(6886):243-4 [12015591.001]
  • [Cites] J Bacteriol. 2002 Aug;184(16):4601-11 [12142430.001]
  • [Cites] Vaccine. 2003 Sep 8;21(25-26):3912-8 [12922126.001]
  • [Cites] Mol Microbiol. 2004 Apr;52(2):451-69 [15066033.001]
  • [Cites] Immunol Rev. 2004 Apr;198:203-15 [15199964.001]
  • [Cites] Genetika. 1983 Jul;19(7):1081-90 [6194044.001]
  • [Cites] Infect Immun. 1984 Mar;43(3):895-900 [6365786.001]
  • [Cites] Infect Immun. 1987 Mar;55(3):572-8 [3818085.001]
  • [Cites] Infect Immun. 1988 May;56(5):1242-8 [2833444.001]
  • [Cites] J Bacteriol. 1990 Feb;172(2):1062-9 [1688838.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):86-93 [1846140.001]
  • [Cites] Infect Immun. 1991 Mar;59(3):1106-11 [1997413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):953-64 [1522243.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Jun;37(6):1247-52 [8392306.001]
  • [Cites] J Bacteriol. 1994 Jul;176(13):4043-51 [8021186.001]
  • [Cites] Infect Immun. 1994 Nov;62(11):5183-6 [7927803.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] J Bacteriol. 1995 Feb;177(3):799-804 [7836315.001]
  • [Cites] Infect Immun. 1995 Jul;63(7):2541-8 [7790067.001]
  • [Cites] J Bacteriol. 1995 Jul;177(13):3843-54 [7601852.001]
  • [Cites] Science. 1996 Jul 19;273(5273):367-70 [8662526.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2483-9 [8698470.001]
  • [Cites] Clin Microbiol Rev. 1997 Jan;10(1):35-66 [8993858.001]
  • [Cites] Infect Immun. 1998 Oct;66(10):4611-23 [9746557.001]
  • [Cites] J Mol Evol. 1998 Nov;47(5):625-30 [9797413.001]
  • [Cites] Infect Immun. 1998 Dec;66(12):5731-42 [9826348.001]
  • [Cites] Science. 1954 Jun 18;119(3103):877 [13168383.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2232-44 [15784567.001]
  • [Cites] J Infect Dis. 2005 Jun 1;191(11):1907-12 [15871125.001]
  • [Cites] Curr Issues Mol Biol. 2005 Jul;7(2):197-212 [16053250.001]
  • [Cites] Annu Rev Microbiol. 2005;59:69-89 [15847602.001]
  • [Cites] EMBO Rep. 2005 Oct;6(10):992-7 [16170309.001]
  • [Cites] Infect Immun. 2005 Nov;73(11):7236-42 [16239518.001]
  • [Cites] Infect Immun. 2005 Nov;73(11):7324-31 [16239530.001]
  • [Cites] Infect Immun. 2006 Feb;74(2):1381-6 [16428789.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8778-83 [10922034.001]
  • (PMID = 18025094.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM070977; United States / NIAID NIH HHS / AI / R21 AI074820; United States / NIAID NIH HHS / AI / R21 AI074820-02; United States / NIAID NIH HHS / AI / R01 AI039575; United States / NIAID NIH HHS / AI / R01 AI051520-05; United States / NIAID NIH HHS / AI / R01 AI051520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / Virulence Factors; 9007-36-7 / Complement System Proteins
  • [Other-IDs] NLM/ PMC2223467
  •  go-up   go-down


Advertisement
4. Rastawicki W: [Humoral response to recombinant YeuB, Ail, YadA and Inv proteins of Yersinia enterocolitica in patients with yersiniosis]. Med Dosw Mikrobiol; 2009;61(1):21-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Humoral response to recombinant YeuB, Ail, YadA and Inv proteins of Yersinia enterocolitica in patients with yersiniosis].
  • [Transliterated title] Humoralna odpowiedź na rekombinowane białka YeuB, Ail, YadA i Inv pałeczek Yersinia enterocolitica w przebiegu jersiniozy u ludzi.
  • Recombinant YeuB, Ail, YadA and Inv proteins of Y enterocolitica were expressing in E. coli BL21 (DE3) using the pET-30 Ek/LIC expression vector.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517812.001).
  • [ISSN] 0025-8601
  • [Journal-full-title] Medycyna doświadczalna i mikrobiologia
  • [ISO-abbreviation] Med Dosw Mikrobiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Bacterial Proteins; 0 / Immunoglobulins; 0 / Recombinant Proteins; 0 / YadA protein, Yersinia; 0 / YeuB protein, Yersinia enterocolitica; 114073-91-5 / invasin, Yersinia
  •  go-up   go-down


5. Kirjavainen V, Jarva H, Biedzka-Sarek M, Blom AM, Skurnik M, Meri S: Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog; 2008;4(8):e1000140
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein.
  • The major Y. enterocolitica serum resistance determinants include outer membrane proteins YadA and Ail.
  • To identify the C4bp receptors on Y. enterocolitica serotype O:3 surface, a set of mutants expressing YadA, Ail, O-ag, and OC in different combinations was tested for the ability to bind C4bp.
  • The studies showed that both YadA and Ail acted as C4bp receptors.
  • Ail-mediated C4bp binding, however, was blocked by the O-ag and OC, and could be observed only with mutants lacking these LPS structures.
  • These findings show that Y. enterocolitica uses two proteins, YadA and Ail, to bind C4bp.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 1995 Feb;177(3):799-804 [7836315.001]
  • [Cites] Infect Immun. 1995 Dec;63(12):4837-48 [7591144.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2506-14 [8698473.001]
  • [Cites] Infect Immun. 2001 Jun;69(6):3685-91 [11349031.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6764-70 [11359834.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8427-35 [11113124.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(5):1053-62 [11555286.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7293-303 [11705900.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1886-94 [11823523.001]
  • [Cites] Biochemistry. 2002 Jul 30;41(30):9349-57 [12135356.001]
  • [Cites] Infect Immun. 2002 Sep;70(9):5185-92 [12183569.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6352-60 [12444142.001]
  • [Cites] Mol Microbiol. 2003 Jan;47(1):103-18 [12492857.001]
  • [Cites] Mol Microbiol. 2003 Nov;50(4):1125-39 [14622404.001]
  • [Cites] EMBO J. 2004 Feb 25;23(4):701-11 [14765110.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4598-606 [15383594.001]
  • [Cites] Infect Immun. 2004 Nov;72(11):6633-41 [15501796.001]
  • [Cites] J Immunol. 1996 Oct 1;157(7):3021-9 [8816411.001]
  • [Cites] Clin Microbiol Rev. 1997 Jan;10(1):35-66 [8993858.001]
  • [Cites] Clin Microbiol Rev. 1997 Apr;10(2):257-76 [9105754.001]
  • [Cites] Infect Immun. 1997 Sep;65(9):3638-43 [9284130.001]
  • [Cites] Infect Immun. 1997 Nov;65(11):4367-77 [9353007.001]
  • [Cites] Proteins. 1998 Jun 1;31(4):391-405 [9626699.001]
  • [Cites] J Exp Med. 1998 Aug 17;188(4):671-80 [9705949.001]
  • [Cites] Mol Microbiol. 1999 Mar;31(5):1443-62 [10200964.001]
  • [Cites] J Biol Chem. 1999 Jul 2;274(27):19237-45 [10383431.001]
  • [Cites] Cell Microbiol. 2005 Apr;7(4):529-38 [15760453.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2232-44 [15784567.001]
  • [Cites] Infect Immun. 2005 Jun;73(6):3431-9 [15908371.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17142-7 [16275906.001]
  • [Cites] J Struct Biol. 2006 Aug;155(2):154-61 [16675268.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Nat Rev Microbiol. 2008 Feb;6(2):132-42 [18197169.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] Infect Immun. 1992 Sep;60(9):3763-70 [1323535.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Infect Immun. 1993 Aug;61(8):3129-36 [8335343.001]
  • [Cites] Infect Immun. 1994 Apr;62(4):1252-61 [8132332.001]
  • [Cites] Infect Immun. 1994 Apr;62(4):1275-81 [8132334.001]
  • [Cites] Infect Immun. 1994 Nov;62(11):5183-6 [7927803.001]
  • [Cites] Mol Microbiol. 1993 Dec;10(5):995-1011 [7934875.001]
  • [Cites] Infect Immun. 2000 Mar;68(3):1608-19 [10678980.001]
  • [Cites] Infect Immun. 2000 Apr;68(4):2205-14 [10722621.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5328-36 [10799895.001]
  • [Cites] EMBO J. 2000 Nov 15;19(22):5989-99 [11080146.001]
  • [Cites] J Exp Med. 2001 Feb 5;193(3):281-95 [11157049.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1058-66 [11287977.001]
  • [Cites] J Exp Med. 1978 Jul 1;148(1):207-22 [670886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Apr;76(4):1648-52 [377280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Dec;76(12):6596-600 [293746.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1604-7 [6257680.001]
  • [Cites] Nucleic Acids Res. 1981 Jan 24;9(2):309-21 [6259625.001]
  • [Cites] Infect Immun. 1981 Feb;31(2):775-82 [7216474.001]
  • [Cites] Anal Biochem. 1981 Oct;117(1):136-46 [7316186.001]
  • [Cites] Infect Immun. 1982 Feb;35(2):605-11 [7056577.001]
  • [Cites] Infect Immun. 1983 Apr;40(1):166-71 [6832830.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(11):3461-5 [6222381.001]
  • [Cites] Biochem J. 1983 Mar 1;209(3):847-56 [6223625.001]
  • [Cites] J Bacteriol. 1984 Jun;158(3):1033-6 [6725209.001]
  • [Cites] J Appl Bacteriol. 1984 Jun;56(3):355-63 [6146593.001]
  • [Cites] Gene. 1985;33(1):103-19 [2985470.001]
  • [Cites] Infect Immun. 1985 Jun;48(3):782-6 [2987130.001]
  • [Cites] Infect Immun. 1987 Sep;55(9):2247-54 [2887516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1657-61 [2964038.001]
  • [Cites] J Bacteriol. 1989 Jul;171(7):3732-9 [2661534.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):5054-8 [2544889.001]
  • [Cites] J Immunol. 1990 Jan 1;144(1):204-8 [2136880.001]
  • [Cites] J Bacteriol. 1990 Feb;172(2):1062-9 [1688838.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(3):1183-7 [2300577.001]
  • [Cites] J Bacteriol. 1990 Jun;172(6):3152-62 [2160939.001]
  • [Cites] Gut. 1990 Sep;31(9):1011-5 [2210445.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):156-60 [1987115.001]
  • [Cites] J Bacteriol. 1991 Mar;173(5):1677-85 [1999387.001]
  • [Cites] Immunol Res. 1991;10(1):28-42 [1830895.001]
  • [Cites] Infect Immun. 1992 Jan;60(1):189-95 [1729182.001]
  • [Cites] J Bacteriol. 1992 Jan;174(1):84-91 [1729227.001]
  • [Cites] J Bacteriol. 1992 Feb;174(4):1360-9 [1370953.001]
  • [Cites] Infect Immun. 1992 Mar;60(3):870-5 [1311707.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] Infect Immun. 1994 Dec;62(12):5568-75 [7525487.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):375-86 [7995956.001]
  • (PMID = 18769718.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia enterocolitica; 0 / Antibodies, Bacterial; 0 / Bacterial Outer Membrane Proteins; 0 / Complement C4b-Binding Protein; 0 / O Antigens; 0 / YadA protein, Yersinia; 80295-50-7 / Complement C4b; 9001-32-5 / Fibrinogen
  • [Other-IDs] NLM/ PMC2516929
  •  go-up   go-down


6. Sacco C, Ciapini A, Santomauro F, Dei R, Donato R: [Evaluation of the Yersinia enterocolitica pathogenicity through some phenotypic and genotypic characters: CRMOX agar positivity and presence of the ail gene]. Ann Ig; 2005 Nov-Dec;17(6):501-7
Hazardous Substances Data Bank. AGAR-AGAR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the Yersinia enterocolitica pathogenicity through some phenotypic and genotypic characters: CRMOX agar positivity and presence of the ail gene].
  • [Transliterated title] Valutazione della patogenicità di Yersinia enterocolitica attraverso alcuni caratteri fenotipici e genotipici: positività su CRMOX agar e presenza del gene ail.
  • Sixty-nine strains of Y. enterocolitica isolated from environmental and human matrices (waste water, food and faeces) were studied in order to evidence the presence of ail gene, calcium-dependency and Congo Red absorption for pathogenic strains identification.
  • Out of 24 clinical strains, the ail gene was present in 21 (87%), among which 79% were CRMOX-positive as well.
  • On the contrary, none of the 45 environmental strains showed the ail gene although only one (isolated from cooked vegetables) was CRMOX agar positive.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. C.I. DIRECT RED 28 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523709.001).
  • [ISSN] 1120-9135
  • [Journal-full-title] Annali di igiene : medicina preventiva e di comunità
  • [ISO-abbreviation] Ann Ig
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Oxalates; 3U05FHG59S / Congo Red; 9002-18-0 / Agar
  •  go-up   go-down


7. Biedzka-Sarek M, Venho R, Skurnik M: Role of YadA, Ail, and Lipopolysaccharide in Serum Resistance of Yersinia enterocolitica Serotype O:3. Infect Immun; 2005 Apr;73(4):2232-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of YadA, Ail, and Lipopolysaccharide in Serum Resistance of Yersinia enterocolitica Serotype O:3.
  • Yersinia enterocolitica expresses several potential complement resistance factors: the outer membrane proteins YadA and Ail as well as lipopolysaccharide (LPS).
  • To study the contribution of these factors to the survival of Y. enterocolitica serotype O:3 in nonimmune human serum, we constructed 23 mutant strains of Y. enterocolitica O:3 expressing different combinations of YadA, Ail, LPS O antigen, and LPS outer core.
  • Kinetic killing tests revealed that the most potent single-serum resistance factor needed for long-term survival was YadA; Ail was also indispensable, but it provided short-term survival and delayed the bacterial killing.
  • On the contrary, the LPS O antigen and outer core, when in combination with YadA, Ail, or both, had a minor and often negative effect on serum resistance.
  • At later time points (15 and 30 min) it had to be accompanied by YadA, Ail, and outer core.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Immunol. 1991 Apr-May;28(4-5):375-82 [1829503.001]
  • [Cites] Microb Pathog. 1991 Jan;10(1):47-59 [1857198.001]
  • [Cites] Infect Immun. 1992 Jan;60(1):189-95 [1729182.001]
  • [Cites] J Immunol. 1992 Feb 1;148(3):827-36 [1730875.001]
  • [Cites] Infect Immun. 1992 Mar;60(3):870-5 [1311707.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] Infect Immun. 1992 Oct;60(10):3986-93 [1398910.001]
  • [Cites] J Exp Med. 1992 Dec 1;176(6):1625-30 [1281213.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Infect Immun. 1993 Aug;61(8):3129-36 [8335343.001]
  • [Cites] Infect Immun. 1994 Apr;62(4):1252-61 [8132332.001]
  • [Cites] J Bacteriol. 2000 Sep;182(18):5114-20 [10960095.001]
  • [Cites] J Bacteriol. 2001 Mar;183(6):1928-37 [11222590.001]
  • [Cites] Infect Immun. 1997 Oct;65(10):4022-9 [9317002.001]
  • [Cites] J Exp Med. 1998 Mar 2;187(5):743-52 [9480984.001]
  • [Cites] Infect Immun. 1998 Apr;66(4):1427-31 [9529063.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3349-54 [9531294.001]
  • [Cites] Mol Microbiol. 1999 Mar;31(5):1443-62 [10200964.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8427-35 [11113124.001]
  • [Cites] Eur J Immunol. 2001 Jun;31(6):1674-84 [11385611.001]
  • [Cites] Appl Environ Microbiol. 2001 Dec;67(12):5634-42 [11722917.001]
  • [Cites] Infect Immun. 2002 Feb;70(2):491-7 [11796574.001]
  • [Cites] Int J Med Microbiol. 2002 Feb;291(6-7):455-62 [11890544.001]
  • [Cites] FEMS Immunol Med Microbiol. 2003 May 15;36(1-2):33-9 [12727363.001]
  • [Cites] Adv Exp Med Biol. 2003;529:249-51 [12756766.001]
  • [Cites] J Bacteriol. 2003 Jul;185(13):3735-44 [12813066.001]
  • [Cites] J Immunol. 2004 May 15;172(10):6195-201 [15128807.001]
  • [Cites] Gene. 1977;2(2):95-113 [344137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Apr;76(4):1648-52 [377280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Aug;78(8):5118-21 [6946459.001]
  • [Cites] J Immunol. 1983 Feb;130(2):845-9 [6848598.001]
  • [Cites] Infect Immun. 1983 Apr;40(1):166-71 [6832830.001]
  • [Cites] J Bacteriol. 1983 Apr;154(1):269-77 [6187729.001]
  • [Cites] J Appl Bacteriol. 1984 Jun;56(3):355-63 [6146593.001]
  • [Cites] Infect Immun. 1986 Oct;54(1):85-9 [3531020.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand C. 1987 Feb;95(1):27-34 [3554894.001]
  • [Cites] Clin Exp Immunol. 1987 May;68(2):266-74 [3652518.001]
  • [Cites] Infect Immun. 1988 Jan;56(1):40-4 [3335408.001]
  • [Cites] J Bacteriol. 1988 Jun;170(6):2575-83 [2836362.001]
  • [Cites] Infect Immun. 1989 Jul;57(7):1984-9 [2731980.001]
  • [Cites] J Bacteriol. 1991 Mar;173(5):1677-85 [1999387.001]
  • [Cites] J Immunol. 1991 Apr 1;146(7):2345-51 [1706395.001]
  • [Cites] Methods Enzymol. 1994;235:386-405 [8057911.001]
  • [Cites] Mol Microbiol. 1995 Aug;17(3):575-94 [8559076.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2506-14 [8698473.001]
  • [Cites] Genome Res. 1995 Nov;5(4):404-7 [8750200.001]
  • (PMID = 15784567.001).
  • [ISSN] 0019-9567
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Complement C3; 0 / O Antigens; 0 / YadA protein, Yersinia
  • [Other-IDs] NLM/ PMC1087390
  •  go-up   go-down


8. Kolodziejek AM, Sinclair DJ, Seo KS, Schnider DR, Deobald CF, Rohde HN, Viall AK, Minnich SS, Hovde CJ, Minnich SA, Bohach GA: Phenotypic characterization of OmpX, an Ail homologue of Yersinia pestis KIM. Microbiology; 2007 Sep;153(Pt 9):2941-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic characterization of OmpX, an Ail homologue of Yersinia pestis KIM.
  • For Yersinia enterocolitica and Yersinia pseudotuberculosis, Ail, YadA and Inv, have been implicated in these processes.
  • Genomic analysis of two Y. pestis strains revealed four loci with sequence homology to Ail.
  • The mature protein has a predicted molecular mass of 17.47 kDa, shares approximately 70 % sequence identity with Y. enterocolitica Ail, and has an identical homologue, designated Ail, in the Y. pestis CO92 database.
  • The parental strain (and a merodiploid control strain) expressed OmpX at 28 and 37 degrees C, and the protein was detectable throughout all phases of growth.
  • These results suggest that Y. pestis OmpX shares functional homology with Y. enterocolitica Ail in adherence, internalization into epithelial cells and serum resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768237.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016454; United States / NCRR NIH HHS / RR / P20 RR15587; United States / NIAID NIH HHS / AI / U54AI57141
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Proteome; EC 3.- / Hydrolases
  •  go-up   go-down


9. Nole-Wilson S, Tranby TL, Krizek BA: AINTEGUMENTA-like (AIL) genes are expressed in young tissues and may specify meristematic or division-competent states. Plant Mol Biol; 2005 Mar;57(5):613-28
The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AINTEGUMENTA-like (AIL) genes are expressed in young tissues and may specify meristematic or division-competent states.
  • We report expression analyses of seven Arabidopsis genes most closely related to the floral development gene AINTEGUMENTA (ANT) and show that all AINTEGUMENTA-like (AIL) genes are transcribed in multiple tissues during development.
  • Our results are consistent with AIL genes having roles in specification of meristematic or division-competent states.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988559.001).
  • [ISSN] 0167-4412
  • [Journal-full-title] Plant molecular biology
  • [ISO-abbreviation] Plant Mol. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AINTEGUMENTA protein, Arabidopsis; 0 / Arabidopsis Proteins; 0 / DNA, Bacterial; 0 / DNA-Binding Proteins; 0 / PLT1 protein, Arabidopsis; 0 / PLT2 protein, Arabidopsis; 0 / RNA, Messenger; 0 / T-DNA; 0 / Transcription Factor AP-2; 0 / Transcription Factors
  •  go-up   go-down


10. Cheyne BM, Van Dyke MI, Anderson WB, Huck PM: The detection of Yersinia enterocolitica in surface water by quantitative PCR amplification of the ail and yadA genes. J Water Health; 2010 Sep;8(3):487-99
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of Yersinia enterocolitica in surface water by quantitative PCR amplification of the ail and yadA genes.
  • In this study, quantitative PCR (qPCR)-based methods targeting the Yersinia virulence genes ail and yadA were used to survey the Grand River watershed in southern Ontario, Canada.
  • Initial testing of reference strains showed that ail and yadA PCR assays were specific for pathogenic biotypes of Y. enterocolitica; however the genes were also detected in one clinical Yersinia intermedia isolate.
  • A survey of surface water from the Grand River watershed showed that both genes were detected at five sampling locations, with the ail and yadA genes detected in 38 and 21% of samples, respectively.
  • A screening of Yersinia strains isolated from the watershed showed that the ail gene was detected in three Y. enterocolitica 1A/O:5 isolates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375478.001).
  • [ISSN] 1477-8920
  • [Journal-full-title] Journal of water and health
  • [ISO-abbreviation] J Water Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / DNA, Bacterial; 0 / Virulence Factors; 0 / YadA protein, Yersinia
  •  go-up   go-down


11. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML.
  • Supported by: European LeukemiaNet, AIL, AIRC, FIRB 2006, Fondazione del Monte di Bologna e Ravenna, Strategico di Ateneo, GIMEMA Onlus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Muehlenbein CE, Klein RW, Liepa AM, Babineaux SM, Wielage RC, Schwartzberg LS: The importance of histology when evaluating the cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e17533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data from the randomized controlled clinical trial and a mixed treatment comparison model (Vansteenkiste et al, Proc.
  • RESULTS: In all patients regardless of histology, using Cis/Pem led to an incremental cost per life-year gained (LYG) of $104,577 vs. Cis/Gem and $231,291 vs. Carb/Pac.
  • In the subset of patients with nonsquamous NSCLC (adenocarcinoma, large cell, or NOS), the incremental cost per LYG was $83,537 vs. Cis/Gem and $178,613 vs. Carb/Pac.
  • Further specifying the population to include only those with adenocarcinoma or large cell NSCLC yielded an incremental cost per LYG of $72,325 vs. Cis/Gem and $132,547 vs. Carb/Pac.
  • The incremental cost per LYG for Carb/Pac/Bev vs. Cis/Pem was more than $300,000.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963793.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Berry SR, Neumann PJ, Bell C, Nadler E, Evans WC, Palmer J, Strevel E, Ubel PA: What price for a year of life? A survey of U.S. and Canadian oncologists. J Clin Oncol; 2009 May 20;27(15_suppl):6565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both U.S. and Cdn oncologists were asked to indicate what they "thought was 'good value for money' expressed as cost per life-year gained (LYG)."
  • In contrast, when asked directly to indicate CE ratios that were good value for the money outside of the clinical scenario, 70% (U.S.) and 64% (Canada) of respondents indicated values of less than $100,000 per LYG.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963803.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Iacobucci I, Storlazzi C, Lonetti A, Ferrari A, Messina M, Cilloni D, Papayannidis C, Baccarani M, Foà R, Martinelli G: IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report. J Clin Oncol; 2009 May 20;27(15_suppl):11005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11005 Expression of BCR-ABL1 in hematopoietic stem cells can alone induce a chronic myeloid leukemia (CML) but cooperating oncogenic lesions are required for the generation of a blastic leukemia.
  • To identify oncogenic sub-microscopic lesions that cooperate with BCR-ABL1 to induce ALL, by high resolution single nucleotide polymorphism (SNP) arrays (250K NspI and SNP 6.0, Affymetrix) we studied 106 patients (pts) with de novo adult BCR-ABL1-positive ALL.
  • The most frequent somatic copy number alteration was deletion on 7p12 of IKZF1 (68/106, 64%), which encodes the transcription factor Ikaros required for the earliest stages of lymphoid lineage commitment.
  • Univariate analysis showed that the IKZF1 deletion is a negative prognostic marker influencing the cumulative incidence of relapse (10.1 months for pts with deletion vs 56.1 months for wild-type pts, p=0.0103) and disease-free survival (DFS) (10.1 months vs 32.1 months, respectively, p=0.0229).
  • Supported by European LeukemiaNet, AIL, AIRC, FIRB 2006, Strategico di Ateneo, GIMEMA Onlus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Norum J, Nieder C, Kondo M: Sunitinib, sorafenib, temsirolimus, or bevacizumab in the treatment of metastatic renal cell carcinoma (RCC): A review of health economic evaluations. J Clin Oncol; 2009 May 20;27(15_suppl):e17539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17539 Background: Renal cell carcinoma (RCC) is the most prevalent kidney cancer and the 5-year overall survival figure in metastatic disease (mRCC) is about 10%.
  • RESULTS: The review reveals figures of cost per LYG or QALY in the range €22,648 to €203,692, depending on line setting and drug focused.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963791.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Papayannidis C, Iacobucci I, Soverini S, Paolini S, Cilloni D, Messa F, Pane F, Ottaviani E, Baccarani M, Martinelli G: Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. J Clin Oncol; 2009 May 20;27(15_suppl):7080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The third patient, in progression disease, received the 5 days MK-0457 schedule.
  • After one cycle of MK-0457, a complete recovery of the pulmonary disease and a complete hematologic response were obtained.
  • Supported by: European LeukemiaNet, AIL, AIRC, FIRB 2006, Fondazione del Monte di Bologna e Ravenna, Merck Sharp & Dohme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961473.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Balakrishna K, Murali HS, Batra HV: Cloning, expression and characterization of attachment-invasion locus protein (Ail) of Yersinia enterocolitica and its utilization in rapid detection by immunoassays. Lett Appl Microbiol; 2010 Feb;50(2):131-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cloning, expression and characterization of attachment-invasion locus protein (Ail) of Yersinia enterocolitica and its utilization in rapid detection by immunoassays.
  • AIMS: Rapid detection of pathogenic Yersinia enterocolitica isolates by using antisera raised against recombinant attachment-invasion locus (Ail) protein.
  • METHODS AND RESULTS: The complete gene (471 bp) encoding for the Ail protein was amplified by PCR and cloned in pQE 30 UA vector.
  • Western blot analysis with the sera raised against recombinant Ail protein exhibited reaction at 17 kDa region of the native Ail protein present in pathogenic Y. enterocolitica standard strains and strains isolated from pork samples suggesting that the antigenicity of recombinant Ail protein was similar to that of native Ail protein.
  • Nonpathogenic Y. enterocolitica and the other species of Yersinia, namely, Y. pseudotuberculosis, Y. intermedia, Y. kristenseni, Y. fredrickseni and also the Enterobacteriaceae organisms tested were not found reacting to polyclonal antisera against this recombinant Ail protein.
  • CONCLUSION: The antibodies raised against recombinant Ail protein could specifically identify pathogenic Y. enterocolitica strains both by indirect plate ELISA and Western blot immunoassay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002570.001).
  • [ISSN] 1472-765X
  • [Journal-full-title] Letters in applied microbiology
  • [ISO-abbreviation] Lett. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Antibodies, Bacterial; 0 / Bacterial Outer Membrane Proteins; 0 / Recombinant Proteins
  •  go-up   go-down


18. Eroshenko GA, Odinokov GN, Kukleva LM, Krasnov IaM, Kutyrev VV: [Sequence analysis of the yadA, inv, and ail genes and their expression in the main and nonmain Yersinia pestis subspecies and Yersinia pseudotuberculosis]. Genetika; 2010 Jun;46(6):734-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sequence analysis of the yadA, inv, and ail genes and their expression in the main and nonmain Yersinia pestis subspecies and Yersinia pseudotuberculosis].
  • The nucleotide sequences of the inv, yadA, and ail adhesin-invasin genes were analyzed in 24 strains of the main and nonmain Yersinia pestis subspecies, which were isolated from natural plague foci in Russia and neighbor countries, and ten Y. pseudotuberculosis strains.
  • All of the five plague agent subspecies (main, caucasica, altaica, ulegeica, and hissarica) had the inv and yadA genes altered by insertion of the IS element and a single nucleotide deletion, respectively, as was earlier observed for the Y. pestis strains KIM and CO92.
  • The ail gene of the main and ulegeica subspecies had a missense mutation, which replaced Val138 with Phe in the Ail protein.
  • The strains of the caucasica subspecies had an AGT insertion in the ail gene, resulting in Ser148 insertion in the polypeptide chain.
  • The changes in the ail sequence probably exerted no effect on ail expression, since the strains of all subspecies were resistant to blood serum complement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734763.001).
  • [ISSN] 0016-6758
  • [Journal-full-title] Genetika
  • [ISO-abbreviation] Genetika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / DNA Transposable Elements; 0 / Virulence Factors; 0 / YadA protein, Yersinia; 114073-91-5 / invasin, Yersinia
  •  go-up   go-down


19. Platt-Samoraj A, Ugorski M, Szweda W, Szczerba-Turek A, Wojciech K, Procajło Z: Analysis of the presence of ail, ystA and ystB genes in Yersinia enterocolitica strains isolated from aborting sows and aborted fetuses. J Vet Med B Infect Dis Vet Public Health; 2006 Sep;53(7):341-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the presence of ail, ystA and ystB genes in Yersinia enterocolitica strains isolated from aborting sows and aborted fetuses.
  • Forty-five Yersinia enterocolitica strains isolated from aborted fetuses and placentas and from vaginal and rectal swabs of aborting sows were subjected to serotyping, biochemical typing and polymerase chain reaction multiplex analyses to detect the presence of the ail, yst A and ystB genes.
  • As expected, the Y. enterocolitica strains of bioserotype 4/O:3 contained ail and ystA genes, while strains of biotype 1A contained only the ystB gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930279.001).
  • [ISSN] 0931-1793
  • [Journal-full-title] Journal of veterinary medicine. B, Infectious diseases and veterinary public health
  • [ISO-abbreviation] J. Vet. Med. B Infect. Dis. Vet. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / Bacterial Toxins; 0 / Enterotoxins; 0 / heat-stable enterotoxin (Yersinia)
  •  go-up   go-down


20. Felek S, Krukonis ES: The Yersinia pestis Ail protein mediates binding and Yop delivery to host cells required for plague virulence. Infect Immun; 2009 Feb;77(2):825-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Yersinia pestis Ail protein mediates binding and Yop delivery to host cells required for plague virulence.
  • The mutants that emerged contained insertions within the ail (attachment and invasion locus) gene of Y. pestis.
  • A reconstructed mutant with a single deletion in the ail locus (y1324) was severely defective for delivery of Yops to HEp-2 human epithelial cells and significantly defective for delivery of Yops to THP-1 human monocytes.
  • Although the ail mutant showed only a modest decrease in cell binding capacity in vitro, the KIM5 Deltaail mutant exhibited a >3,000-fold-increased 50% lethal dose in mice.
  • Thus, the Ail protein is critical for both Y. pestis type III secretion in vitro and infection in mice.

  • MedlinePlus Health Information. consumer health - Plague.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1993 Feb 25;361(6414):730-2 [8441468.001]
  • [Cites] J Gen Microbiol. 1992 Aug;138 Pt 8:1679-87 [1527508.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Infect Immun. 1995 Jul;63(7):2541-8 [7790067.001]
  • [Cites] Infect Immun. 1996 Jan;64(1):375-9 [8557370.001]
  • [Cites] EMBO J. 1995 Dec 1;14(23):5957-64 [8846788.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2483-9 [8698470.001]
  • [Cites] Clin Microbiol Rev. 1997 Jan;10(1):35-66 [8993858.001]
  • [Cites] Infect Immun. 1997 May;65(5):1659-68 [9125544.001]
  • [Cites] Mol Microbiol. 1998 Mar;27(5):953-65 [9535085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13658-63 [9811856.001]
  • [Cites] Infect Immun. 1998 Dec;66(12):5755-62 [9826351.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52 [9841674.001]
  • [Cites] J Exp Med. 1998 Dec 7;188(11):2127-37 [9841926.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1645-50 [9990078.001]
  • [Cites] Infect Immun. 1999 Sep;67(9):4851-61 [10456941.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1920-3 [10489373.001]
  • [Cites] Mol Microbiol. 2005 May;56(3):590-603 [15819617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17786-91 [16306265.001]
  • [Cites] Infect Immun. 2006 Mar;74(3):1516-27 [16495522.001]
  • [Cites] Science. 2006 May 26;312(5777):1211-4 [16728640.001]
  • [Cites] PLoS Pathog. 2005 Oct;1(2):e16 [16228016.001]
  • [Cites] FEMS Microbiol Lett. 2006 Sep;262(2):158-62 [16923070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13514-9 [16938880.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1066-73 [16980981.001]
  • [Cites] Infect Immun. 2006 Oct;74(10):5636-44 [16988239.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] PLoS Pathog. 2008 Jan;4(1):e3 [18193942.001]
  • [Cites] PLoS One. 2008;3(2):e1688 [18301765.001]
  • [Cites] Microbiology. 2008 Jun;154(Pt 6):1802-12 [18524935.001]
  • [Cites] Structure. 1999 Oct 15;7(10):1301-9 [10545325.001]
  • [Cites] J Biotechnol. 2000 Apr 14;79(1):63-72 [10817342.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5978-83 [10811905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5 [10829079.001]
  • [Cites] Mol Microbiol. 2000 May;36(3):737-48 [10844661.001]
  • [Cites] Infect Immun. 2000 Aug;68(8):4523-30 [10899851.001]
  • [Cites] Mol Microbiol. 2000 Aug;37(3):515-27 [10931345.001]
  • [Cites] Eur J Cell Biol. 2000 Oct;79(10):659-71 [11089914.001]
  • [Cites] Science. 2000 Nov 24;290(5496):1594-7 [11090361.001]
  • [Cites] FEBS Lett. 2001 Aug 24;504(1-2):69-72 [11522299.001]
  • [Cites] FEBS Lett. 2001 Aug 31;504(3):173-8 [11532450.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(5):1053-62 [11555286.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5373-82 [11574469.001]
  • [Cites] Nature. 2001 Oct 4;413(6855):523-7 [11586360.001]
  • [Cites] Mol Microbiol. 2001 Nov;42(3):689-703 [11722735.001]
  • [Cites] J Bacteriol. 2002 Aug;184(16):4601-11 [12142430.001]
  • [Cites] Microb Pathog. 2002 Dec;33(6):265-77 [12495673.001]
  • [Cites] Mol Microbiol. 2003 Feb;47(3):807-23 [12535078.001]
  • [Cites] Adv Exp Med Biol. 2003;529:79-84 [12756732.001]
  • [Cites] Infect Immun. 2003 Aug;71(8):4595-607 [12874339.001]
  • [Cites] Mol Microbiol. 2004 Jun;52(5):1363-73 [15165239.001]
  • [Cites] Infect Immun. 2004 Aug;72(8):4589-602 [15271919.001]
  • [Cites] Infect Immun. 1988 May;56(5):1242-8 [2833444.001]
  • [Cites] Nature. 1988 Aug 11;334(6182):522-4 [3043229.001]
  • [Cites] Infect Immun. 1989 Apr;57(4):1200-10 [2925246.001]
  • [Cites] J Exp Med. 1989 Nov 1;170(5):1727-36 [2572672.001]
  • [Cites] Mol Microbiol. 1990 Apr;4(4):657-67 [2191183.001]
  • [Cites] Infect Immun. 1990 Aug;58(8):2569-77 [2164509.001]
  • [Cites] Gene. 1991 Jan 2;97(1):39-47 [1847347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1187-91 [1705028.001]
  • [Cites] J Bacteriol. 1991 Sep;173(17):5298-307 [1679429.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] Cell. 1993 Apr 23;73(2):381-93 [8386592.001]
  • (PMID = 19064637.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / Bacterial Proteins; 0 / DNA Transposable Elements; 0 / Membrane Transport Proteins; 0 / Virulence Factors; 0 / YscC protein, Yersinia pestis
  • [Other-IDs] NLM/ PMC2632051
  •  go-up   go-down


21. Biedzka-Sarek M, Salmenlinna S, Gruber M, Lupas AN, Meri S, Skurnik M: Functional mapping of YadA- and Ail-mediated binding of human factor H to Yersinia enterocolitica serotype O:3. Infect Immun; 2008 Nov;76(11):5016-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional mapping of YadA- and Ail-mediated binding of human factor H to Yersinia enterocolitica serotype O:3.
  • These include two outer membrane proteins, YadA and Ail, that function as adhesins and complement resistance (CR) factors.
  • Both YadA and Ail bind the functionally active complement alternative pathway regulator factor H (FH).
  • Twenty-eight mutants having short (7 to 41 amino acids) internal deletions within the neck and stalk of YadA and two complement-sensitive site-directed Ail mutants were constructed to map the CR and FH binding regions of YadA and Ail.
  • On the other hand, the complement-sensitive Ail mutants were not affected in FH binding.
  • Our results also suggested that Ail- and YadA-mediated CR does not depend solely on FH binding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 1988 May;56(5):1242-8 [2833444.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1657-61 [2964038.001]
  • [Cites] J Bacteriol. 1990 Feb;172(2):1062-9 [1688838.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):156-60 [1987115.001]
  • [Cites] J Bacteriol. 1991 Mar;173(5):1677-85 [1999387.001]
  • [Cites] Infect Immun. 1992 Jan;60(1):189-95 [1729182.001]
  • [Cites] J Bacteriol. 1992 Mar;174(6):2047-51 [1548243.001]
  • [Cites] Mol Microbiol. 1992 Feb;6(3):395-409 [1552853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] Infect Immun. 1993 Aug;61(8):3129-36 [8335343.001]
  • [Cites] Infect Immun. 1994 Apr;62(4):1252-61 [8132332.001]
  • [Cites] Infect Immun. 1995 Jan;63(1):149-53 [7806351.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5663-70 [7499851.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2506-14 [8698473.001]
  • [Cites] Genome Res. 1995 Nov;5(4):404-7 [8750200.001]
  • [Cites] J Exp Med. 1998 Aug 17;188(4):671-80 [9705949.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7471-80 [15585873.001]
  • [Cites] J Bacteriol. 2005 Feb;187(4):1317-23 [15687195.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2232-44 [15784567.001]
  • [Cites] Adv Protein Chem. 2005;70:37-78 [15837513.001]
  • [Cites] Infect Immun. 2006 Apr;74(4):2007-14 [16552029.001]
  • [Cites] J Struct Biol. 2006 Aug;155(2):154-61 [16675268.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):7292-301 [17513779.001]
  • [Cites] Clin Exp Immunol. 2008 Jan;151(1):14-24 [18081691.001]
  • [Cites] Mol Microbiol. 2008 Feb;67(3):584-96 [18093091.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3426-35 [18292569.001]
  • [Cites] Infect Immun. 2008 Sep;76(9):4100-9 [18625735.001]
  • [Cites] PLoS Pathog. 2008;4(8):e1000140 [18769718.001]
  • [Cites] Infect Immun. 1983 Apr;40(1):166-71 [6832830.001]
  • [Cites] Structure. 1999 Oct 15;7(10):1301-9 [10545325.001]
  • [Cites] Mol Microbiol. 2000 Jul;37(1):192-206 [10931316.001]
  • [Cites] EMBO J. 2000 Nov 15;19(22):5989-99 [11080146.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8427-35 [11113124.001]
  • [Cites] Int J Med Microbiol. 2001 Aug;291(3):209-18 [11554561.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(5):1053-62 [11555286.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12642-8 [11812795.001]
  • [Cites] J Struct Biol. 2002 Jan-Feb;137(1-2):41-53 [12064932.001]
  • [Cites] Mol Immunol. 2003 Jan;39(10):547-56 [12431388.001]
  • [Cites] Infect Immun. 2003 Jun;71(6):3587-96 [12761144.001]
  • [Cites] J Bacteriol. 2003 Jul;185(13):3735-44 [12813066.001]
  • [Cites] EMBO J. 2004 Feb 25;23(4):701-11 [14765110.001]
  • [Cites] Protein Sci. 2004 May;13(5):1356-64 [15075409.001]
  • [Cites] J Exp Med. 1976 Nov 2;144(5):1147-63 [62817.001]
  • [Cites] J Exp Med. 1977 Jul 1;146(1):257-70 [301546.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Apr;76(4):1648-52 [377280.001]
  • [Cites] Nature. 1980 Jan 10;283(5743):224-6 [7350546.001]
  • [Cites] Infect Immun. 1980 Feb;27(2):682-5 [7380546.001]
  • [Cites] Infect Immun. 1981 Sep;33(3):870-6 [7287174.001]
  • [Cites] J Infect Dis. 1983 Jan;147(1):107-15 [6822745.001]
  • [Cites] Infect Immun. 1983 Sep;41(3):921-30 [6885171.001]
  • [Cites] J Bacteriol. 1984 Jun;158(3):1033-6 [6725209.001]
  • [Cites] J Appl Bacteriol. 1984 Jun;56(3):355-63 [6146593.001]
  • [Cites] Gene. 1985;33(1):103-19 [2985470.001]
  • [Cites] Infect Immun. 1985 Jun;48(3):782-6 [2987130.001]
  • [Cites] Curr Top Microbiol Immunol. 1985;118:29-51 [3902382.001]
  • [Cites] Clin Exp Immunol. 1987 May;68(2):266-74 [3652518.001]
  • [Cites] J Bacteriol. 1989 Jul;171(7):3732-9 [2661534.001]
  • (PMID = 18765735.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / YadA protein, Yersinia; 80295-65-4 / Complement Factor H
  • [Other-IDs] NLM/ PMC2573320
  •  go-up   go-down


22. Polydorides AD, Mukherjee B, Gruber SB, McKenna BJ, Appelman HD, Greenson JK: Adenoma-infiltrating lymphocytes (AILs) are a potential marker of hereditary nonpolyposis colorectal cancer. Am J Surg Pathol; 2008 Nov;32(11):1661-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoma-infiltrating lymphocytes (AILs) are a potential marker of hereditary nonpolyposis colorectal cancer.
  • Patients with hereditary nonpolyposis colorectal cancer syndrome (HNPCC) develop microsatellite-unstable colorectal cancers that tend to be more proximally located and are histologically more likely to show high numbers of tumor-infiltrating lymphocytes, a lack of dirty necrosis, mucinous or poor differentiation, and a Crohn-like host immune response, when compared with microsatellite-stable cancers.
  • Adenomas from HNPCC patients were more likely to contain high numbers of adenoma-infiltrating lymphocytes (AILs) with 12 of 16 (75%) adenomas having >or=5 AILs per high-power field (HPF) as opposed to 4 of 32 (12%) adenomas in the control group (P=0.00003).
  • Therefore, increased numbers of AILs and decreased numbers of apoptoses in colorectal adenomas are simple and inexpensive markers that raise the possibility of HNPCC.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1758-62 [9392616.001]
  • [Cites] Semin Surg Oncol. 1995 Nov-Dec;11(6):406-10 [8607009.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1805-13 [10362805.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):139-43 [15654793.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2525-35 [15735733.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1143-9 [15842591.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1150-3 [15842592.001]
  • [Cites] Gastroenterology. 2000 May;118(5):829-34 [10784581.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):17-24 [10963375.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2417-22 [11413533.001]
  • [Cites] Gut. 2002 Feb;50(2):228-34 [11788565.001]
  • [Cites] Gut. 2002 Mar;50(3):382-6 [11839719.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):563-70 [12717242.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1407-17 [14576473.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):42-8 [14699485.001]
  • [Cites] Gut. 1995 Mar;36(3):385-90 [7698698.001]
  • [Cites] J Pathol. 1995 May;176(1):37-44 [7616355.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):160-70 [15858139.001]
  • [Cites] N Engl J Med. 2005 May 5;352(18):1851-60 [15872200.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1095-101 [15731775.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):80-93; discussion 94-5 [16284887.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):831-8 [16784982.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):632-41 [16511680.001]
  • [Cites] JAMA. 2006 Sep 27;296(12):1507-17 [17003399.001]
  • [Cites] Int J Colorectal Dis. 2007 Jul;22(7):739-48 [17109103.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1093-8 [17919485.001]
  • [Cites] Dig Dis Sci. 2008 Jun;53(6):1660-8 [17999188.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):3221-7 [10652615.001]
  • [Cites] In Vivo. 1995 May-Jun;9(3):173-6 [8562876.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):627-34 [8616753.001]
  • [Cites] In Vivo. 1997 Sep-Oct;11(5):393-4 [9427041.001]
  • (PMID = 18753941.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA081488
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS417252; NLM/ PMC3500084
  •  go-up   go-down


23. Morcillo F, Gallard A, Pillot M, Jouannic S, Aberlenc-Bertossi F, Collin M, Verdeil JL, Tregear JW: EgAP2-1, an AINTEGUMENTA-like (AIL) gene expressed in meristematic and proliferating tissues of embryos in oil palm. Planta; 2007 Nov;226(6):1353-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EgAP2-1, an AINTEGUMENTA-like (AIL) gene expressed in meristematic and proliferating tissues of embryos in oil palm.
  • We identified and characterized EgAP2-1, which codes for a protein that contains two AP2 domains similar to those of the transcription factor BABYBOOM (BBM) and more generally AINTEGUMENTA-like (AIL) proteins of the AP2 subgroup.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628826.001).
  • [ISSN] 0032-0935
  • [Journal-full-title] Planta
  • [ISO-abbreviation] Planta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Plant Proteins; 0 / Transcription Factors
  •  go-up   go-down


24. Hasty P: Rapamycin: the cure for all that ails. J Mol Cell Biol; 2010 Feb;2(1):17-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin: the cure for all that ails.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805415.001).
  • [ISSN] 1759-4685
  • [Journal-full-title] Journal of molecular cell biology
  • [ISO-abbreviation] J Mol Cell Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


25. Rogers DG, Aliano VA: Metastatic angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat. J Vet Diagn Invest; 2009 May;21(3):390-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat.
  • A subcutaneous mass removed from the right rear leg of a 17-year-old, spayed, female Domestic Shorthair cat was characterized histopathologically by granulomatous inflammation, sheets of large atypical lymphoid cells, and necrosis.
  • The walls of the small and medium caliber blood vessels were invaded transmurally by atypical lymphoid cells.
  • A diagnosis of angioinvasive lymphoma (AIL), or lymphomatoid granulomatosis, was made based on histopathologic findings.
  • The cat was euthanized 2 months later because of recurrence of the mass and elevated serum alanine aminotransferase activity, and a necropsy was performed.
  • The histopathologic lesion of AIL was seen in the skin and subcutis of the right rear leg, and neoplastic cell infiltrates were seen in adjacent skeletal muscle, right superficial inguinal lymph node, liver, and spleen.
  • Although the cat had received a Rabies virus vaccine subcutaneously in the right rear leg 6 months earlier, the AIL lesion was not typical of vaccine-induced sarcomas.
  • The AIL in this cat was unusual because the extrapulmonary metastases involved the skin and subcutis.
  • [MeSH-major] Cat Diseases / diagnosis. Lymphomatoid Granulomatosis / veterinary. Neoplasms, Connective Tissue / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407098.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Conde C: Curing what ails us: new report says Texans' health declining. Tex Med; 2009 Mar;105(3):18-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curing what ails us: new report says Texans' health declining.

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263301.001).
  • [ISSN] 1938-3223
  • [Journal-full-title] Texas medicine
  • [ISO-abbreviation] Tex Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Drut R, Drut RM: Angiocentric immunoproliferative lesion and angiocentric lymphoma of lymph node in children. A report of two cases. J Clin Pathol; 2005 May;58(5):550-2
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiocentric immunoproliferative lesion and angiocentric lymphoma of lymph node in children. A report of two cases.
  • AIM: To report two examples of an angiocentric immunoproliferative lesion (AIL) and angiocentric angiodestructive lymphoma (AL) presenting in lymph nodes in children.
  • Most commonly involving extranodal sites, AIL/AL rarely presents in the spleen and lymph nodes.
  • Histological and immunohistochemistry studies revealed an Epstein-Barr virus positive (EBV+), large B cell (CD20 and CD30+) AIL with large areas of necrosis, the whole resembling lymphomatoid granulomatosis.
  • Histology and immunohistochemistry revealed an EBV-, large T cell (CD45RO, CD56, and CD30+) AL, presenting the features of so called angiocentric T cell/natural killer cell lymphoma, nasal type.
  • CONCLUSIONS: The term AIL/AL refers to a heterogeneous group of conditions not unique to a particular type of lymphoid cell.
  • These lesions are easily recognised by the histopathologist because of their extremely unusual angiocentric pattern.
  • Although rare, AIL/AL may present as nodal lesions in children ab initio.
  • [MeSH-major] Immunoproliferative Disorders / pathology. Lymph Nodes / pathology. Lymphatic Diseases / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Child, Preschool. Female. Humans. Immunohistochemistry. Lymphomatoid Granulomatosis / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):93-5 [11244444.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):555-7 [12835306.001]
  • [Cites] J Neurol Sci. 2003 Sep 15;213(1-2):67-76 [12873757.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4280-3 [6272972.001]
  • [Cites] Pediatr Pathol. 1988;8(4):395-400 [3062603.001]
  • [Cites] Am J Hematol. 1989 Feb;30(2):104-11 [2913758.001]
  • [Cites] Med Pediatr Oncol. 1999 Jun;32(6):447-9 [10358706.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):439-47 [1318000.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):623-31 [8179077.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1300-12 [7573693.001]
  • [Cites] Am J Clin Pathol. 1996 Jul;106(1):69-77 [8701936.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):77-81 [9065724.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):378-84 [2155307.001]
  • (PMID = 15858132.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770650
  •  go-up   go-down


28. Lovinger DM, Homanics GE: Tonic for what ails us? high-affinity GABAA receptors and alcohol. Alcohol; 2007 May;41(3):139-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonic for what ails us? high-affinity GABAA receptors and alcohol.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Alcohol Health Res World. 1997;21(2):127-31 [15704348.001]
  • [Cites] J Neurosci. 2004 Nov 24;24(47):10679-86 [15564584.001]
  • [Cites] Pharmacol Ther. 2005 Jul;107(1):80-98 [15963352.001]
  • [Cites] J Neurophysiol. 2005 Dec;94(6):4491-501 [16162835.001]
  • [Cites] J Neurosci. 2005 Dec 14;25(50):11553-63 [16354913.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Mar;316(3):1360-8 [16272217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8546-51 [16581914.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8540-5 [16698930.001]
  • [Cites] J Neurophysiol. 2006 Jul;96(1):433-41 [16624993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15230-5 [17005728.001]
  • [Cites] Nat Neurosci. 2007 Jan;10(1):40-8 [17159992.001]
  • [Cites] Alcohol Clin Exp Res. 1991 Jun;15(3):406-11 [1877727.001]
  • [Cites] Pharmacol Biochem Behav. 1991 Jul;39(3):803-7 [1686108.001]
  • [Cites] Brain Res. 1992 Nov 13;595(2):220-7 [1334772.001]
  • [Cites] Eur J Pharmacol. 1992 Dec 2;224(2-3):173-81 [1281777.001]
  • [Cites] Nature. 1993 Jan 28;361(6410):356-9 [7678923.001]
  • [Cites] FEBS Lett. 1993 Jun 14;324(2):140-2 [8389719.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Mar;268(3):1388-95 [8138953.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Apr;269(1):157-63 [7513357.001]
  • [Cites] Brain Res. 1994 May 30;647(1):97-105 [8069709.001]
  • [Cites] Eur J Pharmacol. 1994 Jul 15;268(2):209-14 [7957642.001]
  • [Cites] J Neurosci. 2004 Apr 14;24(15):3746-51 [15084654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):5049-54 [8643527.001]
  • [Cites] Physiol Rev. 1997 Jan;77(1):1-20 [9016298.001]
  • [Cites] Mol Pharmacol. 1997 Apr;51(4):588-96 [9106623.001]
  • [Cites] Nature. 1997 Sep 25;389(6649):385-9 [9311780.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Feb;284(2):768-76 [9454826.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Feb;22(1):259-65 [9514316.001]
  • [Cites] Brain Res. 1998 Sep 14;805(1-2):116-22 [9733942.001]
  • [Cites] Psychopharmacology (Berl). 1998 Sep;139(1-2):2-19 [9768538.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Oct;22(7):1516-24 [9802537.001]
  • [Cites] Eur J Neurosci. 1999 Jan;11(1):233-40 [9987027.001]
  • [Cites] Neuropharmacology. 1999 Feb;38(2):253-65 [10218866.001]
  • [Cites] Pharmacol Biochem Behav. 1999 May;63(1):93-9 [10340528.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10532-8 [11136737.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):88-92 [11343119.001]
  • [Cites] Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):76S-81S [11391054.001]
  • [Cites] Alcohol Clin Exp Res. 2001 Dec;25(12):1708-18 [11781502.001]
  • [Cites] J Comp Neurol. 2002 Apr 29;446(2):179-97 [11932935.001]
  • [Cites] Alcohol Clin Exp Res. 2002 Apr;26(4):457-62 [11981120.001]
  • [Cites] Nat Neurosci. 2002 Aug;5(8):721-2 [12118257.001]
  • [Cites] Curr Top Med Chem. 2002 Aug;2(8):869-85 [12171577.001]
  • [Cites] Brain Res. 2003 Feb 14;963(1-2):165-77 [12560122.001]
  • [Cites] Brain Res Mol Brain Res. 2003 Feb 20;110(2):289-97 [12591165.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2053-8 [12566570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14439-44 [14623958.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15218-23 [14625373.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1512-4 [15001778.001]
  • [Cites] Behav Genet. 2004 Jul;34(4):453-63 [15082942.001]
  • [Cites] J Neurosci. 2004 Sep 22;24(38):8379-82 [15385620.001]
  • [Cites] Alcohol. 1984 Jan-Feb;1(1):59-62 [6543611.001]
  • [Cites] Br J Pharmacol. 1985 Jul;85(3):675-81 [2992670.001]
  • [Cites] Science. 1986 Dec 5;234(4781):1243-7 [3022383.001]
  • [Cites] Life Sci. 1987 Aug 3;41(5):611-9 [3600196.001]
  • [Cites] Brain Res. 1987 Jun 23;414(1):22-34 [3620923.001]
  • [Cites] Brain Res. 1988 Jul 12;455(2):377-80 [2900060.001]
  • [Cites] Pharmacol Biochem Behav. 1988 Jun;30(2):501-10 [2845447.001]
  • [Cites] Pharmacol Biochem Behav. 1989 Jan;32(1):163-7 [2543989.001]
  • [Cites] Psychopharmacology (Berl). 1989;99(3):333-6 [2512588.001]
  • [Cites] Brain Res. 1990 Jan 22;507(2):332-6 [2186844.001]
  • [Cites] Nature. 1990 Aug 16;346(6285):648-51 [2166916.001]
  • [Cites] Eur J Pharmacol. 1990 Oct 2;187(1):127-30 [1703076.001]
  • [Cites] Neuron. 1991 Jul;7(1):27-33 [1712603.001]
  • [Cites] Nat Neurosci. 2005 Mar;8(3):339-45 [15696164.001]
  • (PMID = 17521844.001).
  • [ISSN] 0741-8329
  • [Journal-full-title] Alcohol (Fayetteville, N.Y.)
  • [ISO-abbreviation] Alcohol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AA000407-06
  • [Publication-type] Editorial; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 0 / Receptors, GABA-A; 3K9958V90M / Ethanol
  • [Number-of-references] 63
  • [Other-IDs] NLM/ NIHMS27062; NLM/ PMC2043151
  •  go-up   go-down


29. Kershaw P, Anderson L: Is a pan-Canadian early child development system possible? Yes, when we redress what ails Canadian culture. Paediatr Child Health; 2009 Dec;14(10):685-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is a pan-Canadian early child development system possible? Yes, when we redress what ails Canadian culture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119820.001).
  • [ISSN] 1918-1485
  • [Journal-full-title] Paediatrics & child health
  • [ISO-abbreviation] Paediatr Child Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2807815
  • [Keywords] NOTNLM ; Early childhood development / Outcomes / Social paediatrics
  •  go-up   go-down


30. Pal I, Gupta A, Sengupta S: An attempt to define the type of biopsy in a sinonasal lesion showing bony erosion. Indian J Otolaryngol Head Neck Surg; 2010 Jan;62(1):92-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An attempt to define the type of biopsy in a sinonasal lesion showing bony erosion.
  • OBJECTIVES: To present a case of sino-nasal destructive mass initially diagnosed as an inflammatory lesion following punch biopsy from the lesion however the post surgical histopathology was diagnostic of Grade 2 angiocentric immunoproliferative lesion (AIL).
  • Repeated punch biopsies from the mass were suggestive of an inflammatory lesion.
  • RESULT: The patient underwent surgical exenteration of the mass and the final histopathology report suggested AIL Grade 2.
  • CONCLUSION: Initial superficial punch biopsies lead to incorrect diagnosis leading to an unnecessary surgical exenteration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1995 Oct;48(10):946-9 [8537496.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):255-63 [11904341.001]
  • [Cites] Acta Dermatovenerol Alp Pannonica Adriat. 2007 Jun;16(2):73-6 [17992462.001]
  • (PMID = 23120692.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450158
  • [Keywords] NOTNLM ; Angiocentric immunoproliferative lesion / Angiocentricity / Incisional biopsy
  •  go-up   go-down


31. Kolodziejek AM, Schnider DR, Rohde HN, Wojtowicz AJ, Bohach GA, Minnich SA, Hovde CJ: Outer membrane protein X (Ail) contributes to Yersinia pestis virulence in pneumonic plague and its activity is dependent on the lipopolysaccharide core length. Infect Immun; 2010 Dec;78(12):5233-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outer membrane protein X (Ail) contributes to Yersinia pestis virulence in pneumonic plague and its activity is dependent on the lipopolysaccharide core length.
  • Here, we tested the contribution of OmpX to disease progression in the fully virulent Y. pestis CO92 strain by engineering a deletion mutant and comparing its ability in mediating pneumonic plague to that of the wild type in two animal models.
  • The deletion of OmpX delayed the time to death up to 48 h in a mouse model and completely attenuated virulence in a rat model of disease.
  • The rat model, which is most similar to humans, highlighted the critical role of serum resistance in disease.

  • MedlinePlus Health Information. consumer health - Plague.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Structure. 2000 Jun 15;8(6):585-92 [10873859.001]
  • [Cites] Infect Immun. 2010 Jun;78(6):2644-52 [20368351.001]
  • [Cites] Microb Pathog. 2001 Feb;30(2):49-57 [11162185.001]
  • [Cites] FEMS Microbiol Lett. 2001 Apr 13;197(2):229-33 [11313139.001]
  • [Cites] Infect Immun. 2002 Feb;70(2):491-7 [11796574.001]
  • [Cites] Trends Microbiol. 2002 Feb;10(2):74-9 [11827808.001]
  • [Cites] Infect Immun. 2003 Jul;71(7):3673-81 [12819047.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Oct;29(4):432-8 [14500254.001]
  • [Cites] Mol Microbiol. 2004 Jan;51(1):215-25 [14651623.001]
  • [Cites] Mol Microbiol. 2004 Jun;52(5):1363-73 [15165239.001]
  • [Cites] FEBS Lett. 2004 Jul 2;569(1-3):27-30 [15225603.001]
  • [Cites] J Bacteriol. 1966 Mar;91(3):953-62 [5929770.001]
  • [Cites] J Bacteriol. 1982 Aug;151(2):718-22 [7047495.001]
  • [Cites] Microbiol Rev. 1985 Mar;49(1):1-32 [2580220.001]
  • [Cites] J Bacteriol. 1990 Nov;172(11):6568-72 [2172217.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):156-60 [1987115.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):161-7 [1702778.001]
  • [Cites] Infect Immun. 1991 Mar;59(3):1106-11 [1997413.001]
  • [Cites] J Bacteriol. 1992 Jan;174(1):84-91 [1729227.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):953-64 [1522243.001]
  • [Cites] Infect Immun. 1994 Nov;62(11):5183-6 [7927803.001]
  • [Cites] J Bacteriol. 1995 Feb;177(3):799-804 [7836315.001]
  • [Cites] Infect Immun. 1995 Jul;63(7):2541-8 [7790067.001]
  • [Cites] Science. 1996 Jan 5;271(5245):64-7 [8539601.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 May;37(6):976-86 [8631641.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;216:39-81 [8791735.001]
  • [Cites] Infect Immun. 1997 Sep;65(9):3638-43 [9284130.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11059-64 [9736689.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):5114-9 [9988760.001]
  • [Cites] Science. 1954 Jun 18;119(3103):877 [13168383.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2232-44 [15784567.001]
  • [Cites] Biochem Soc Trans. 2005 Apr;33(Pt 2):331-4 [15787599.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1427-39 [15855643.001]
  • [Cites] Infect Immun. 2005 Nov;73(11):7324-31 [16239530.001]
  • [Cites] J Endotoxin Res. 2006;12(1):3-9 [16420739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5526-30 [16567636.001]
  • [Cites] Protein Sci. 2006 Apr;15(4):884-9 [16522795.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1066-73 [16980981.001]
  • [Cites] Infect Immun. 2006 Oct;74(10):5636-44 [16988239.001]
  • [Cites] Science. 2007 Jan 26;315(5811):509-13 [17255510.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L748-59 [17071722.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Appl Environ Microbiol. 2007 Sep;73(18):5750-9 [17644638.001]
  • [Cites] Adv Exp Med Biol. 2007;603:88-96 [17966406.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):578-87 [18025093.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3426-35 [18292569.001]
  • [Cites] J Pept Sci. 2008 Apr;14(4):535-43 [17985396.001]
  • [Cites] Microbiology. 2008 Jun;154(Pt 6):1802-12 [18524935.001]
  • [Cites] Microbiology. 2008 Jul;154(Pt 7):2131-8 [18599840.001]
  • [Cites] Infect Immun. 2009 Jan;77(1):317-26 [18936182.001]
  • [Cites] Infect Immun. 2009 Feb;77(2):825-36 [19064637.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):910-21 [19164505.001]
  • [Cites] Vaccine. 2008 Dec 30;26 Suppl 8:I62-6 [19388167.001]
  • [Cites] PLoS One. 2009;4(6):e6000 [19543392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3070-5 [20133627.001]
  • [Cites] Infect Immun. 2000 Aug;68(8):4523-30 [10899851.001]
  • (PMID = 20837715.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U54 AI057141; United States / NCRR NIH HHS / RR / P20 RR016454; United States / NCRR NIH HHS / RR / P20 RR015587; United States / NIAID NIH HHS / AI / U54AI57141; United States / NCRR NIH HHS / RR / P20 RR15587
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ail protein, Yersinia pestis; 0 / Bacterial Outer Membrane Proteins; 0 / Lipopolysaccharides; 0 / Virulence Factors
  • [Other-IDs] NLM/ PMC2981323
  •  go-up   go-down


32. Hu WS, Li PC, Cheng CY: Correlation between ceftriaxone resistance of Salmonella enterica serovar Typhimurium and expression of outer membrane proteins OmpW and Ail/OmpX-like protein, which are regulated by BaeR of a two-component system. Antimicrob Agents Chemother; 2005 Sep;49(9):3955-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between ceftriaxone resistance of Salmonella enterica serovar Typhimurium and expression of outer membrane proteins OmpW and Ail/OmpX-like protein, which are regulated by BaeR of a two-component system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Microbiol. 2000 Apr;3(2):165-70 [10745001.001]
  • [Cites] Cell. 1993 Jun 4;73(5):857-71 [8098993.001]
  • [Cites] Eur J Biochem. 2000 May;267(10):2871-81 [10806384.001]
  • [Cites] Semin Cell Dev Biol. 2001 Jun;12(3):215-23 [11428914.001]
  • [Cites] FEMS Microbiol Rev. 2002 Mar;26(1):3-16 [12007640.001]
  • [Cites] J Bacteriol. 2002 Aug;184(15):4161-7 [12107133.001]
  • [Cites] J Bacteriol. 2002 Aug;184(15):4168-76 [12107134.001]
  • [Cites] J Bacteriol. 2003 Mar;185(6):1851-6 [12618449.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Sep;47(9):3030-3 [12937021.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Apr;48(4):1145-50 [15047514.001]
  • [Cites] Int J Antimicrob Agents. 2004 Jun;23(6):547-55 [15194124.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Oct;48(10):3729-35 [15388427.001]
  • [Cites] J Infect Dis. 1987 Nov;156(5):751-7 [2821125.001]
  • [Cites] Science. 1994 Apr 15;264(5157):375-82 [8153624.001]
  • [Cites] Science. 1994 Apr 15;264(5157):382-8 [8153625.001]
  • [Cites] Science. 1994 Apr 15;264(5157):388-93 [8153626.001]
  • [Cites] J Bacteriol. 1998 Sep;180(17):4686-92 [9721312.001]
  • [Cites] Electrophoresis. 1998 Aug;19(11):1941-9 [9740054.001]
  • [Cites] J Bacteriol. 1999 Jun;181(11):3578-81 [10348872.001]
  • [Cites] Antimicrob Agents Chemother. 2000 May;44(5):1223-8 [10770755.001]
  • (PMID = 16127081.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Outer Membrane Proteins; 0 / Cephalosporins; 0 / DNA Transposable Elements; 75J73V1629 / Ceftriaxone
  • [Other-IDs] NLM/ PMC1195446
  •  go-up   go-down


33. Hu WS, Lin JF, Lin YH, Chang HY: Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother; 2009 Aug;53(8):3248-55
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 2000 May;44(5):1223-8 [10770755.001]
  • [Cites] Microbiol Mol Biol Rev. 2000 Dec;64(4):672-93 [11104814.001]
  • [Cites] JAMA. 2000 Dec 27;284(24):3151-6 [11135779.001]
  • [Cites] Mol Microbiol. 2002 Nov;46(3):687-98 [12410826.001]
  • [Cites] J Bacteriol. 2002 Dec;184(23):6490-8 [12426336.001]
  • [Cites] J Antimicrob Chemother. 2003 Jan;51(1):9-11 [12493781.001]
  • [Cites] Infect Immun. 2003 Jun;71(6):3310-9 [12761113.001]
  • [Cites] Gene. 2003 Jun 5;311:153-63 [12853150.001]
  • [Cites] Curr Opin Infect Dis. 2003 Oct;16(5):467-72 [14502000.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Apr;48(4):1145-50 [15047514.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Oct;48(10):3729-35 [15388427.001]
  • [Cites] J Infect Dis. 1987 Nov;156(5):751-7 [2821125.001]
  • [Cites] Antimicrob Agents Chemother. 1990 Sep;34(9):1715-9 [2285283.001]
  • [Cites] J Bacteriol. 1993 Oct;175(19):6299-313 [8407802.001]
  • [Cites] Microbiol Rev. 1996 Dec;60(4):575-608 [8987357.001]
  • [Cites] J Bacteriol. 1998 Sep;180(17):4686-92 [9721312.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Nov;42(11):2914-8 [9797225.001]
  • [Cites] Emerg Infect Dis. 2007 Nov;13(11):1681-8 [18217551.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Sep;49(9):3955-8 [16127081.001]
  • [Cites] Microbes Infect. 2006 Jun;8(7):1945-54 [16714134.001]
  • [Cites] Curr Opin Microbiol. 2006 Dec;9(6):605-11 [17055775.001]
  • [Cites] Mol Microbiol. 2006 Dec;62(6):1674-88 [17427289.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 28;361(3):694-9 [17669360.001]
  • [Cites] Mol Cell Proteomics. 2007 Sep;6(9):1527-50 [17446557.001]
  • [Cites] Mol Microbiol. 2007 Dec;66(5):1174-91 [17971080.001]
  • [Cites] J Bacteriol. 2007 Dec;189(24):9066-75 [17933888.001]
  • (PMID = 19470505.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Outer Membrane Proteins; 75J73V1629 / Ceftriaxone
  • [Other-IDs] NLM/ PMC2715640
  •  go-up   go-down


34. Chamiot B, Rizzi C, Gaillon L, Sirieix-Plénet J, Lelièvre J: Redox-switched amphiphilic ionic liquid behavior in aqueous solution. Langmuir; 2009 Feb 3;25(3):1311-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new redox amphiphilic ionic liquid (AIL) containing ferrocene as a redox-active group was synthesized, 1-(11-ferrocenylundecyl)-3-methylimidazolium bromide (Fc11MIm+).
  • Adsorption and aggregation of both reduced and oxidized forms of this ferrocenated AIL in aqueous solution were studied by surface tension measurements.
  • The micellization was favored for the reduced ferrocenated AIL (Fc11MIm+) as compared with the oxidized ferrocenated AIL (Fc+11MIm+).
  • This corroborated the formation of an expanded monolayer of redox active AIL at the interface.
  • The electrochemical behavior of redox active AIL was investigated.
  • Below the cmc, the electrochemical reaction was dominated by ferrocenated AIL adsorbed onto the electrode surface; then above the cmc, it was controlled by the Fc11MIm+ diffusing to the electrode.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125689.001).
  • [ISSN] 0743-7463
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Pucovský V, Harhun MI, Povstyan OV, Gordienko DV, Moss RF, Bolton TB: Close relation of arterial ICC-like cells to the contractile phenotype of vascular smooth muscle cell. J Cell Mol Med; 2007 Jul-Aug;11(4):764-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This work aimed to establish the lineage of cells similar to the interstitial cells of Cajal (ICC), the arterial ICC-like (AIL) cells, which have recently been described in resistance arteries, and to study their location in the artery wall.
  • Segments of guinea-pig mesenteric arteries and single AIL cells freshly isolated from them were used.
  • Confocal imaging of immunostained cells or segments and electron microscopy of artery segments were used to test for the presence and cellular localization of selected markers, and to localize AIL cells in intact artery segments.
  • AIL cells were negative for PGP9.5, a neural marker, and for von Willebrand factor (vWF), an endothelial cell marker.
  • Cell isolation in the presence of latrunculin B, an actin polymerization inhibitor, did not cause the disappearance of AIL cells from cell suspension.
  • The fluorescence of basal lamina protein collagen IV was comparable between the AIL cells and the vascular SMCs and the fluorescence of laminin was higher in AIL cells compared to vascular SMCs.
  • The results suggest that AIL cells are immature or phenotypically modulated vascular SMCs constitutively present in resistance arteries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Physiol (1985). 2001 Jan;90(1):358-68 [11133929.001]
  • [Cites] Auton Neurosci. 2000 Nov 1;84(3):147-61 [11111847.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1146-51 [11451743.001]
  • [Cites] Circ Res. 2001 Dec 7;89(12):1111-21 [11739275.001]
  • [Cites] Basic Res Cardiol. 2002 Jan;97(1):9-16 [11998981.001]
  • [Cites] J Urol. 2002 Jul;168(1):315-22 [12050563.001]
  • [Cites] J Urol. 2002 Aug;168(2):832-6 [12131376.001]
  • [Cites] Results Probl Cell Differ. 2002;38:39-59 [12132398.001]
  • [Cites] Cell Tissue Res. 2002 Oct;310(1):77-84 [12242486.001]
  • [Cites] Circ Res. 2002 Oct 18;91(8):652-5 [12386139.001]
  • [Cites] Cell Calcium. 2003 Apr;33(4):223-39 [12618143.001]
  • [Cites] Curr Atheroscler Rep. 2003 May;5(3):208-13 [12667434.001]
  • [Cites] Cardiovasc Res. 2003 Jun 1;58(3):679-88 [12798442.001]
  • [Cites] J Physiol. 2003 Oct 1;552(Pt 1):119-33 [12897177.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1258-65 [15124016.001]
  • [Cites] Circ Res. 2004 Sep 17;95(6):619-26 [15331453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Jun;70(6):1753-6 [4515934.001]
  • [Cites] Cell Tissue Res. 1977 Feb 14;177(4):503-22 [402216.001]
  • [Cites] Atherosclerosis. 1981 Nov-Dec;40(3-4):347-57 [7332614.001]
  • [Cites] J Neurochem. 1983 Jun;40(6):1542-7 [6343558.001]
  • [Cites] FEBS Lett. 1987 Mar 23;213(2):316-8 [3556584.001]
  • [Cites] Arch Pathol Lab Med. 1988 Oct;112(10):977-86 [3052359.001]
  • [Cites] Exp Cell Res. 1993 Jan;204(1):121-9 [8416790.001]
  • [Cites] Circ Res. 1994 Oct;75(4):669-81 [7923613.001]
  • [Cites] J Clin Invest. 1996 Feb 1;97(3):814-25 [8609239.001]
  • [Cites] J Cell Biol. 1996 Jul;134(2):401-11 [8707825.001]
  • [Cites] FEBS Lett. 1997 Apr 1;405(3):315-20 [9108311.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):665-71 [9108778.001]
  • [Cites] Histochem Cell Biol. 1997 Dec;108(6):513-23 [9450634.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Mar;18(3):333-8 [9514400.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):140-8 [10381920.001]
  • [Cites] Circ Res. 1999 Aug 20;85(4):338-48 [10455062.001]
  • [Cites] J Cell Mol Med. 2005 Apr-Jun;9(2):232-43 [15963246.001]
  • [Cites] J Cell Mol Med. 2005 Apr-Jun;9(2):407-20 [15963260.001]
  • [Cites] J Cell Mol Med. 2005 Jul-Sep;9(3):543-56 [16202204.001]
  • [Cites] Cell Tissue Res. 2005 Jul;321(1):45-55 [15902505.001]
  • [Cites] J Cell Mol Med. 2005 Apr-Jun;9(2):479-523 [15963270.001]
  • [Cites] J Submicrosc Cytol Pathol. 2005 Aug;37(2):109-204 [16335592.001]
  • [Cites] J Cell Mol Med. 2006 Jan-Mar;10(1):243-57 [16563237.001]
  • [Cites] J Cell Mol Med. 2006 Apr-Jun;10(2):429-58 [16796810.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2696-702 [17008593.001]
  • [Cites] Atherosclerosis. 2007 Apr;191(2):259-64 [16787646.001]
  • [Cites] J Physiol. 2000 Jul 15;526 Pt 2:359-66 [10896724.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):503-8 [11304464.001]
  • (PMID = 17760838.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 042293; United Kingdom / Wellcome Trust / / 074724; United Kingdom / Wellcome Trust / / 075112
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytoskeletal Proteins; 0 / von Willebrand Factor; EC 2.7.11.18 / Myosin-Light-Chain Kinase; EC 3.1.2.15 / Ubiquitin Thiolesterase
  • [Other-IDs] NLM/ PMC2121184
  •  go-up   go-down


36. Umeno H, Chitose S, Sato K, Nakashima T: Efficacy of additional injection laryngoplasty after framework surgery. Ann Otol Rhinol Laryngol; 2008 Jan;117(1):5-10
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The purpose of this study was to clarify the efficacy of additional injection laryngoplasty (AIL) after framework surgery (FS), while also trying to identify which patients or procedures were more likely to require AIL to obtain optimal results and to clarify why.
  • The numbers of patients who required AIL were calculated for each type of FS.
  • The voice function after AIL was investigated.
  • RESULTS: The patients who underwent AA required AIL more frequently than did patients who underwent TP.
  • Use of AIL provided better voice function for all patients.
  • CONCLUSIONS: These results indicate that AIL is an effective treatment for patients who still have a glottal gap after undergoing FS.
  • In particular, patients who had AA frequently required AIL, in comparison to patients who had TP, because of the high frequency of an increased bowing ratio after AA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254363.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Marcheix PS, Marcheix B, Siegler J, Bouillet P, Chaynes P, Valleix D, Mabit C: The anterior intermeniscal ligament of the knee: an anatomic and MR study. Surg Radiol Anat; 2009 Jun;31(5):331-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purposes of this study were to identify the presence of the anterior intermeniscal ligament of the knee (AIL), to study its attachment patterns and relationships to other anatomic structures within the knee and to evaluate the potential association of its rupture with other pathology of the knee.
  • RESULTS: AIL was found in nine dissected knees with type I insertion in six cases, type II insertion in three cases.
  • The average distance between AIL and insertion of the anterior cruciate ligament was 12 mm (11-15 mm).
  • Concerning MR study, AIL was found in 34 cases (82.9%).
  • Four (9.75%) ruptures of the AIL were encountered.
  • Where AIL was intact, 14 patients presented meniscal lesions (46.6%).
  • Where AIL was ruptured, three patients presented meniscal lesions (75%).
  • CONCLUSION: The present study demonstrates through anatomical and MR studies that AIL is present in more than 80% of the cases with predominant type I insertion.
  • The association of meniscal and AIL lesions was highlighted demonstrating that AIL is not only an anatomical point of interest but also a clinical and surgical reality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19234659.001).
  • [ISSN] 1279-8517
  • [Journal-full-title] Surgical and radiologic anatomy : SRA
  • [ISO-abbreviation] Surg Radiol Anat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Itoh T, Umekawa K, Rensha K, Minami K, Shoji S, Kitaichi M, Hirata K: [A case of grade I lymphomatoid granulomatosis detected as a solitary lung nodule in a health examination]. Nihon Kokyuki Gakkai Zasshi; 2008 Jan;46(1):50-4
Genetic Alliance. consumer health - Lymphomatoid granulomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of grade I lymphomatoid granulomatosis detected as a solitary lung nodule in a health examination].
  • The pathologic diagnosis of the resected lung was lymphomatoid granulomatosis/angiocentric immunoproliferative lesion (LYG/AIL), grade I.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260311.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Peirce JL, Broman KW, Lu L, Chesler EJ, Zhou G, Airey DC, Birmingham AE, Williams RW: Genome Reshuffling for Advanced Intercross Permutation (GRAIP): simulation and permutation for advanced intercross population analysis. PLoS One; 2008 Apr 23;3(4):e1977
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Advanced intercross lines (AIL) are segregating populations created using a multi-generation breeding protocol for fine mapping complex trait loci (QTL) in mice and other organisms.
  • Applying QTL mapping methods for intercross and backcross populations, often followed by naïve permutation of individuals and phenotypes, does not account for the effect of AIL family structure in which final generations have been expanded and leads to inappropriately low significance thresholds.
  • The critical problem with naïve mapping approaches in AIL populations is that the individual is not an exchangeable unit.
  • METHODOLOGY/PRINCIPAL FINDINGS: The effect of family structure has immediate implications for the optimal AIL creation (many crosses, few animals per cross, and population expansion before the final generation) and we discuss these and the utility of AIL populations for QTL fine mapping.
  • We also describe Genome Reshuffling for Advanced Intercross Permutation, (GRAIP) a method for analyzing AIL data that accounts for family structure.
  • GRAIP permutes a more interchangeable unit in the final generation crosses - the parental genome - and simulating regeneration of a permuted AIL population based on exchanged parental identities.
  • GRAIP determines appropriate genome-wide significance thresholds and locus-specific P-values for AILs and other populations with similar family structures.
  • We contrast GRAIP with naïve permutation using a large densely genotyped mouse AIL population (1333 individuals from 32 crosses).
  • GRAIP also detects an established hippocampus weight locus and a new locus, Hipp9a.
  • CONCLUSIONS AND SIGNIFICANCE: GRAIP determines appropriate genome-wide significance thresholds and locus-specific P-values for AILs and other populations with similar family structures.
  • The effect of family structure has immediate implications for the optimal AIL creation and we discuss these and the utility of AIL populations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mamm Genome. 2000 Aug;11(8):645-8 [10920233.001]
  • [Cites] PLoS One. 2007;2(10):e1036 [17940600.001]
  • [Cites] J Neurosci. 2001 May 15;21(10):3503-14 [11331379.001]
  • [Cites] Genomics. 2001 May 15;74(1):89-104 [11374905.001]
  • [Cites] Genetics. 2001 Sep;159(1):371-87 [11560912.001]
  • [Cites] Hum Hered. 2001;52(3):121-31 [11588394.001]
  • [Cites] Genome Biol. 2001;2(11):RESEARCH0046 [11737945.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):920-34 [11880950.001]
  • [Cites] Genetics. 2002 Mar;160(3):1123-31 [11901128.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):235-6 [12089518.001]
  • [Cites] Neuropsychopharmacology. 2003 Apr;28(4):818; author reply 819 [12655329.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3317-24 [12810665.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1654-64 [12805272.001]
  • [Cites] Genes Brain Behav. 2003 Aug;2(4):238-52 [12953790.001]
  • [Cites] Nat Rev Genet. 2003 Nov;4(11):911-6 [14634638.001]
  • [Cites] Neuroinformatics. 2003;1(4):343-57 [15043220.001]
  • [Cites] BMC Genet. 2004 Apr 29;5:7 [15117419.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1366-73 [15240732.001]
  • [Cites] Mamm Genome. 2004 Aug;15(8):637-47 [15457343.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1133-7 [15514660.001]
  • [Cites] J Dairy Sci. 1990 Sep;73(9):2525-37 [2258496.001]
  • [Cites] Genetics. 1994 Nov;138(3):963-71 [7851788.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Am J Hum Genet. 1996 Jun;58(6):1323-37 [8651310.001]
  • [Cites] Mamm Genome. 1999 Apr;10(4):335-48 [10087289.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Apr;40(5):817-25 [10102277.001]
  • [Cites] Genetics. 2005 Feb;169(2):1133-46 [15545647.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):233-42 [15711545.001]
  • [Cites] Genetics. 2005 May;170(1):283-9 [15716504.001]
  • [Cites] Genetics. 2005 Jul;170(3):1299-311 [15879512.001]
  • [Cites] Mamm Genome. 2005 May;16(5):344-55 [16104382.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):641-9 [11195461.001]
  • (PMID = 18431467.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / U01AA01442501; United States / NIMH NIH HHS / MH / P20 MH062009; United States / NHLBI NIH HHS / HV / HV48141; United States / NIAAA NIH HHS / AA / U01 AA013499; United States / NIAAA NIH HHS / AA / U01AA13499; United States / NIAAA NIH HHS / AA / U24AA135B; United States / NIMH NIH HHS / MH / P20-MH62009; United States / NHLBI NIH HHS / HL / N01HV48141
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2295257
  •  go-up   go-down


40. Zárate G, Chaia AP: Dairy bacteria remove in vitro dietary lectins with toxic effects on colonic cells. J Appl Microbiol; 2009 Mar;106(3):1050-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess in vitro the ability of some dairy bacteria to bind concanavalin A (Con A), peanut agglutinin (PNA) and jacalin (AIL), preventing their toxicity on mouse intestinal epithelial cells (IEC).
  • METHODS AND RESULTS: Con A and AIL reduced significantly IEC viability in vitro, as determined by Trypan Blue dye exclusion or by propidium iodide/fluorescein diacetate/Hoescht staining.
  • Con A and AIL were removed by Propionibacterium acidipropionici and Propionibacterium freudenreichii by binding with specific sugar moieties on the bacterial surface.
  • Adhesion of P. acidipropionici to IEC was reduced but not abolished after binding Con A or AIL.
  • CONCLUSIONS: Removal of Con A or AIL by dairy propionibacteria was effective to avoid the toxic effect against colonic cells in vitro.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19191953.001).
  • [ISSN] 1365-2672
  • [Journal-full-title] Journal of applied microbiology
  • [ISO-abbreviation] J. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lectins; 0 / Plant Lectins; 0 / jacalin; 11028-71-0 / Concanavalin A
  •  go-up   go-down


41. Yu X, Bauer K, Wernhoff P, Ibrahim SM: Using an advanced intercross line to identify quantitative trait loci controlling immune response during collagen-induced arthritis. Genes Immun; 2007 Jun;8(4):296-301
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced intercross line (AIL) is a powerful tool for high-resolution mapping of quantitative trait loci (QTLs).
  • Several AILs have been generated to refine QTLs since the method was proposed about a decade ago.
  • However, no AIL has been used for identifying novel QTLs.
  • Here we used an AIL to test this possibility.
  • We genotyped 308 (DBA/1 x FVB/N) F(11/12) AIL mice with 109 informative markers covering four chromosomes, with an average intermarker distance of 5.5 Mb.
  • Several normally distributed quantitative traits involved in the immune response during the course of collagen-induced arthritis (CIA), such as anti-collagen II antibodies, T-cell subset proportions and reactive oxygen species (ROS) production were taken as phenotypes.
  • Four QTLs, namely Ciaa1, Lctlp1, Lctlp2 and Rosq1, controlling anti-collagen II IgG2a levels, lymph nodes CD8(+) T cell proportion and ROS production were identified with support intervals of 15, 14, 8 and 8 Mb, respectively.
  • Taken together, we successfully used an AIL to identify novel QTLs controlling immune responses during CIA with relatively small support intervals.
  • [MeSH-minor] Animals. Autoantibodies / biosynthesis. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Collagen Type II / immunology. Crosses, Genetic. Female. Male. Mice. Mice, Inbred DBA. Reactive Oxygen Species / metabolism. Sex Characteristics. T-Lymphocyte Subsets / immunology

  • COS Scholar Universe. author profiles.
  • GeneWeaver. GeneWeaver .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361202.001).
  • [ISSN] 1466-4879
  • [Journal-full-title] Genes and immunity
  • [ISO-abbreviation] Genes Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Collagen Type II; 0 / Reactive Oxygen Species
  •  go-up   go-down


42. Potenza MN, Brodkin ES, Yang BZ, Birnbaum SG, Nestler EJ, Gelernter J: Quantitative trait locus analysis identifies rat genomic regions related to amphetamine-induced locomotion and Galpha(i3) levels in nucleus accumbens. Neuropsychopharmacology; 2008 Oct;33(11):2735-46
Hazardous Substances Data Bank. AMPHETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • F(2) progeny derived from parental rat strains F344/NHsd and LEW/NHsd, which differ in responses to drugs of abuse, were used in quantitative trait locus (QTL) analyses to identify genomic regions associated with amphetamine-induced locomotion (AIL) and G-protein levels in the nucleus accumbens (NAc).
  • The most robust QTLs were observed on chromosome 3 (maximal log ratio statistic score (LRS(max))=21.3) for AIL and on chromosome 2 (LRS(max)=22.0) for Galpha(i3).
  • A 'suggestive' QTL (LRS(max)=12.5) was observed for AIL in a region of chromosome 2 that overlaps with the Galpha(i3) QTL.
  • Novelty-induced locomotion (NIL) showed different QTL patterns from AIL, with the most robust QTL on chromosome 13 (LRS(max)=12.2).
  • Specific unique and overlapping genomic regions influence AIL, NIL, and inhibitory G-protein levels in the NAc.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurochem. 2004 Mar;88(5):1211-9 [15009677.001]
  • [Cites] Biol Psychiatry. 2004 Mar 15;55(6):634-41 [15013833.001]
  • [Cites] Biol Psychiatry. 2004 Apr 15;55(8):797-803 [15050860.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jul 5;806(2):81-7 [15171915.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2004 Jul 1;128B(1):94-101 [15211640.001]
  • [Cites] Int Immunol. 2004 Oct;16(10):1507-14 [15339882.001]
  • [Cites] J Neurochem. 2004 Oct;91(2):374-84 [15447670.001]
  • [Cites] Learn Mem. 2004 Sep-Oct;11(5):648-57 [15466321.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):241-7 [7581446.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):82-5 [8782824.001]
  • [Cites] Neuropsychopharmacology. 1996 Nov;15(5):484-90 [8914121.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):471-3 [8944030.001]
  • [Cites] Mol Psychiatry. 1996 Jul;1(3):190-9 [9118343.001]
  • [Cites] Brain Res. 1997 Mar 7;750(1-2):285-92 [9098554.001]
  • [Cites] Behav Genet. 1997 Mar;27(2):125-32 [9145551.001]
  • [Cites] J Neurosci. 1997 Jan 15;17(2):745-54 [8987796.001]
  • [Cites] J Neurosci. 1999 May 15;19(10):4110-22 [10234039.001]
  • [Cites] Mol Psychiatry. 1999 Sep;4(5):453-62 [10523818.001]
  • [Cites] Ann N Y Acad Sci. 2004 Oct;1025:335-44 [15542734.001]
  • [Cites] Neuropsychopharmacology. 2004 Dec;29(12):2126-39 [15213703.001]
  • [Cites] Neurobiol Learn Mem. 2005 Jan;83(1):43-7 [15607687.001]
  • [Cites] Behav Brain Res. 2005 Feb 10;157(1):147-56 [15617781.001]
  • [Cites] Arch Gen Psychiatry. 2005 Jan;62(1):47-55 [15630072.001]
  • [Cites] Eur J Pharmacol. 2005 Jan 31;508(1-3):123-30 [15680262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1737-42 [15665076.001]
  • [Cites] Brain Res. 2005 Feb 9;1034(1-2):162-71 [15713268.001]
  • [Cites] Neuropsychopharmacology. 2005 Mar;30(3):538-49 [15536496.001]
  • [Cites] Psychiatr Genet. 2005 Mar;15(1):71-5 [15722961.001]
  • [Cites] Neuropsychopharmacology. 2005 Apr;30(4):742-6 [15508023.001]
  • [Cites] Mol Psychiatry. 2005 Apr;10(4):336-44 [15583701.001]
  • [Cites] Addict Behav. 2005 May;30(4):859-64 [15833589.001]
  • [Cites] Neuropsychopharmacology. 2005 May;30(5):916-26 [15726118.001]
  • [Cites] Cell Mol Neurobiol. 2005 Jun;25(3-4):553-80 [16075379.001]
  • [Cites] Mamm Genome. 2005 May;16(5):291-305 [16104378.001]
  • [Cites] Neuron. 2005 Oct 20;48(2):303-14 [16242410.001]
  • [Cites] Psychopharmacology (Berl). 2005 Sep;181(2):309-18 [15778876.001]
  • [Cites] AAPS J. 2005;7(2):E353-60 [16353915.001]
  • [Cites] Neuroscience. 2006;137(2):373-83 [16359811.001]
  • [Cites] Neuropsychopharmacology. 2006 Mar;31(3):555-62 [16123776.001]
  • [Cites] Psychopharmacology (Berl). 2006 Mar;185(1):123-32 [16418827.001]
  • [Cites] Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8 [16503828.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Apr;317(1):454-61 [16322355.001]
  • [Cites] Behav Genet. 2006 Jan;36(1):77-86 [16341907.001]
  • [Cites] Nat Neurosci. 2006 May;9(5):605-7 [16633344.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jan;284(1):317-22 [9435194.001]
  • [Cites] Behav Brain Res. 1997 Dec;89(1-2):99-106 [9475618.001]
  • [Cites] J Neurosci. 1998 Apr 15;18(8):3023-34 [9526019.001]
  • [Cites] Pharmacol Biochem Behav. 1998 Apr;59(4):813-8 [9586836.001]
  • [Cites] Am J Med Genet. 1998 May 8;81(3):216-21 [9603607.001]
  • [Cites] Brain Res. 1998 Sep 14;805(1-2):55-68 [9733917.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11792-7 [9751744.001]
  • [Cites] Arch Gen Psychiatry. 1998 Nov;55(11):967-72 [9819064.001]
  • [Cites] Psychopharmacology (Berl). 1998 Nov;140(1):42-51 [9862401.001]
  • [Cites] Mamm Genome. 1998 Dec;9(12):949-55 [9880658.001]
  • [Cites] Pharmacol Biochem Behav. 1999 Feb;62(2):299-305 [9972697.001]
  • [Cites] Mamm Genome. 1999 Apr;10(4):327-34 [10087288.001]
  • [Cites] Physiol Behav. 2005 Jun 2;85(2):167-76 [15885719.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8357-62 [15923261.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2005 Jul 5;136B(1):45-52 [15909294.001]
  • [Cites] Trends Neurosci. 2005 Aug;28(8):436-45 [15982754.001]
  • [Cites] Am J Hum Genet. 2006 May;78(5):759-69 [16642432.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2006 Jun 5;141B(4):387-93 [16649215.001]
  • [Cites] Neuropharmacology. 2006 Jun;50(7):858-64 [16458333.001]
  • [Cites] Biol Psychiatry. 2006 Jun 15;59(12):1151-9 [16566899.001]
  • [Cites] Neuroscience. 2006 Aug 25;141(2):597-605 [16713106.001]
  • [Cites] Peptides. 2006 Aug;27(8):1987-92 [16759749.001]
  • [Cites] J Neurosci. 2006 Aug 9;26(32):8235-42 [16899718.001]
  • [Cites] Nutr Neurosci. 2006 Feb-Apr;9(1-2):81-92 [16910173.001]
  • [Cites] Peptides. 2006 Aug;27(8):1993-2004 [16766084.001]
  • [Cites] Hum Psychopharmacol. 2006 Aug;21(6):367-75 [16915581.001]
  • [Cites] Hum Mol Genet. 2006 Sep 15;15(18):2721-31 [16893910.001]
  • [Cites] J Psychiatry Neurosci. 2006 Sep;31(5):301-13 [16951733.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Sep;85(1):57-65 [16949140.001]
  • [Cites] Hum Mol Genet. 2007 Apr 1;16(7):820-36 [17468183.001]
  • [Cites] Genomics. 2004 Nov;84(5):853-8 [15475264.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8906-10 [7568041.001]
  • [Cites] Pharmacogenetics. 1999 Oct;9(5):607-17 [10591541.001]
  • [Cites] Eur J Neurosci. 1999 Dec;11(12):4419-32 [10594669.001]
  • [Cites] Eur J Pharmacol. 2000 Mar 30;393(1-3):237-42 [10771019.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):128-135 [11102287.001]
  • [Cites] Nature. 2001 Mar 15;410(6826):376-80 [11268215.001]
  • [Cites] Am J Psychiatry. 2001 May;158(5):718-24 [11329392.001]
  • [Cites] Pharmacogenetics. 2001 Apr;11(3):255-64 [11337941.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Aug;298(2):634-43 [11454925.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11042-6 [11572966.001]
  • [Cites] Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):35-69 [11750769.001]
  • [Cites] J Neurosci. 2002 Feb 1;22(3):1165-70 [11826145.001]
  • [Cites] Synapse. 2003 Feb;47(2):117-22 [12454949.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2003 Feb15;117B(1):39-45 [12555233.001]
  • [Cites] J Neurosci. 2003 Feb 1;23(3):742-7 [12574402.001]
  • [Cites] Neuropsychopharmacology. 2003 Aug;28(8):1485-90 [12784114.001]
  • [Cites] Genes Brain Behav. 2003 Jun;2(3):140-51 [12931787.001]
  • [Cites] Genet Epidemiol. 2003;25 Suppl 1:S90-7 [14635174.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Dec;307(3):1038-44 [14551286.001]
  • [Cites] Int J Neuropsychopharmacol. 2004 Mar;7(1):77-97 [14733627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2191-6 [14769920.001]
  • (PMID = 18216777.001).
  • [ISSN] 1740-634X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / DA000366-05; United States / NIDA NIH HHS / DA / DA019039-05; United States / NIDA NIH HHS / DA / R01 DA019039-05; United States / NIDA NIH HHS / DA / K12-DA00167; United States / NIAAA NIH HHS / AA / R01 AA11330; United States / NIDA NIH HHS / DA / R01 DA012849; United States / NIDA NIH HHS / DA / R01 DA12849; United States / NIMH NIH HHS / MH / MH066172-04; United States / NIDA NIH HHS / DA / P01 DA008227; United States / NIMH NIH HHS / MH / K08 MH068586-05; United States / NIMH NIH HHS / MH / P50 MH066172; United States / NIMH NIH HHS / MH / P50 MH066172-04; United States / NIDA NIH HHS / DA / K12 DA000167; United States / NIDA NIH HHS / DA / K12 DA000366-05; United States / NIMH NIH HHS / MH / K08 MH068586; United States / NIDA NIH HHS / DA / K12 DA000167-18; None / None / / K12 DA000167-18; United States / NIDA NIH HHS / DA / DA008227-18; United States / NIAAA NIH HHS / AA / R01 AA011330; United States / NIDA NIH HHS / DA / K12 DA000366; United States / NIDA NIH HHS / DA / R01 DA012849-05; United States / NIDA NIH HHS / DA / R01 DA019039; United States / NIMH NIH HHS / MH / MH068586-05; United States / NIDA NIH HHS / DA / K12-DA00366; United States / NIDA NIH HHS / DA / P01 DA08227; United States / NIDA NIH HHS / DA / P01 DA008227-18; United States / NIAAA NIH HHS / AA / R01 AA011330-08; United States / NIMH NIH HHS / MH / P50 MH66172
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] CK833KGX7E / Amphetamine; EC 3.6.5.1 / GNAI3 protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gi-Go
  • [Other-IDs] NLM/ NIHMS166505; NLM/ PMC2818767
  •  go-up   go-down


43. Carone DA, Benedict RH, Zivadinov R, Singh B, Ambrus JL: Progressive cerebral disease in lymphomatoid granulomatosis causes anterograde amnesia and neuropsychiatric disorder. J Neuroimaging; 2006 Apr;16(2):163-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive cerebral disease in lymphomatoid granulomatosis causes anterograde amnesia and neuropsychiatric disorder.
  • The authors report neuropsychological (NP) and serial quantitative magnetic resonance imaging (MRI) findings of a 29-year-old woman with lymphomatoid granulomatosis (LG).
  • Disease course was characterized by acute psychosis, tremor, fever, seizures, and progressive cognitive impairment.
  • At the time of symptom onset, brain MRI revealed mild lesion volume and normal parenchymal volume.
  • This was followed by dramatic progression of brain lesions and atrophy over 2 years, at which point the patient expired.
  • To our knowledge, this is the first recorded case of LG in which bilateral temporal lobe atrophy is evident and accompanied by anterograde amnesia.
  • [MeSH-major] Amnesia, Anterograde / pathology. Brain Diseases / pathology. Lymphomatoid Granulomatosis / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Atrophy. Disease Progression. Fatal Outcome. Female. Humans. Neuropsychological Tests

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629740.001).
  • [ISSN] 1051-2284
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Felek S, Tsang TM, Krukonis ES: Three Yersinia pestis adhesins facilitate Yop delivery to eukaryotic cells and contribute to plague virulence. Infect Immun; 2010 Oct;78(10):4134-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Y. pestis adhesin Ail facilitates Yop translocation and is required for full virulence in mice.
  • In addition to Ail, plasminogen activator (Pla) and pH 6 antigen (Psa) could mediate Yop translocation to host cells.
  • When cells were pregrown at 28°C and pH 7, the order of importance for adhesins in cell binding and cytotoxicity was Ail > Pla > Psa. Y. pestis grown at 37°C and pH 7 had equal contributions from Ail and Pla but an undetectable role for Psa.
  • At 37°C and pH 6, both Ail and Psa contributed to binding and Yop delivery, while Pla contributed minimally.
  • The expression level of ail was also the highest of the three adhesins in infected mouse tissues.
  • Compared to an ail mutant, additional deletion of psaA (encoding Psa) led to a 130,000-fold increase in the 50% lethal dose for mice relative to that of the KIM5 parental strain.
  • Our results indicate that in addition to Ail, Pla and Psa can serve as environmentally specific adhesins to facilitate Yop secretion, a critical virulence function of Y. pestis.

  • MedlinePlus Health Information. consumer health - Plague.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Pathog. 2008 Jan;4(1):e3 [18193942.001]
  • [Cites] PLoS Med. 2008 Jan 15;5(1):e3 [18198939.001]
  • [Cites] Infect Dis Clin North Am. 2008 Mar;22(1):145-87, vii [18295687.001]
  • [Cites] Microbiology. 2008 Jun;154(Pt 6):1802-12 [18524935.001]
  • [Cites] Infect Immun. 2008 Sep;76(9):4100-9 [18625735.001]
  • [Cites] PLoS Pathog. 2008;4(8):e1000140 [18769718.001]
  • [Cites] J Biol Chem. 2008 Nov 14;283(46):31511-21 [18650418.001]
  • [Cites] J Med Microbiol. 2009 Jan;58(Pt 1):26-36 [19074650.001]
  • [Cites] Infect Immun. 2009 Feb;77(2):825-36 [19064637.001]
  • [Cites] Microbiology. 2009 Feb;155(Pt 2):498-512 [19202098.001]
  • [Cites] J Basic Microbiol. 2009 Feb;49(1):92-9 [18759226.001]
  • [Cites] Infect Immun. 2010 Aug;78(8):3358-68 [20498264.001]
  • [Cites] Methods. 2000 Jun;21(2):179-83 [10816379.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5978-83 [10811905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5 [10829079.001]
  • [Cites] Infect Immun. 2000 Aug;68(8):4523-30 [10899851.001]
  • [Cites] Eur J Cell Biol. 2000 Oct;79(10):659-71 [11089914.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(5):1097-111 [11401715.001]
  • [Cites] FEBS Lett. 2001 Aug 24;504(1-2):69-72 [11522299.001]
  • [Cites] Nature. 2001 Oct 4;413(6855):523-7 [11586360.001]
  • [Cites] Infect Immun. 2002 Mar;70(3):1453-60 [11854232.001]
  • [Cites] Science. 2002 Apr 26;296(5568):733-5 [11976454.001]
  • [Cites] J Bacteriol. 2002 Aug;184(16):4601-11 [12142430.001]
  • [Cites] Microb Pathog. 2002 Dec;33(6):265-77 [12495673.001]
  • [Cites] Mol Microbiol. 2003 Feb;47(3):807-23 [12535078.001]
  • [Cites] J Lipid Res. 2003 Feb;44(2):320-30 [12576514.001]
  • [Cites] Infect Immun. 1986 Feb;51(2):445-54 [3002984.001]
  • [Cites] Nature. 1988 Aug 11;334(6182):522-4 [3043229.001]
  • [Cites] Microb Pathog. 1989 Mar;6(3):203-17 [2739560.001]
  • [Cites] Mol Microbiol. 1990 Apr;4(4):657-67 [2191183.001]
  • [Cites] Infect Immun. 1990 Aug;58(8):2569-77 [2164509.001]
  • [Cites] Gene. 1991 Jan 2;97(1):39-47 [1847347.001]
  • [Cites] Infect Immun. 1991 Dec;59(12):4562-9 [1937815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] J Gen Microbiol. 1992 Aug;138 Pt 8:1679-87 [1527508.001]
  • [Cites] Science. 1992 Nov 6;258(5084):1004-7 [1439793.001]
  • [Cites] Mol Microbiol. 1992 Sep;6(18):2693-704 [1447977.001]
  • [Cites] Cell. 1993 Apr 23;73(2):381-93 [8386592.001]
  • [Cites] Infect Immun. 1993 May;61(5):1846-52 [7682996.001]
  • [Cites] Mol Microbiol. 1993 Apr;8(2):311-24 [8100346.001]
  • [Cites] Infect Immun. 1995 Aug;63(8):3117-24 [7622239.001]
  • [Cites] J Bacteriol. 1995 Oct;177(20):5997-6000 [7592356.001]
  • [Cites] Infect Immun. 1996 Jan;64(1):375-9 [8557370.001]
  • [Cites] EMBO J. 1995 Dec 1;14(23):5957-64 [8846788.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2483-9 [8698470.001]
  • [Cites] FEMS Immunol Med Microbiol. 1996 May;14(1):53-7 [8804976.001]
  • [Cites] Clin Microbiol Rev. 1997 Jan;10(1):35-66 [8993858.001]
  • [Cites] Infect Immun. 1997 May;65(5):1659-68 [9125544.001]
  • [Cites] Mol Microbiol. 1997 May;24(3):499-510 [9179844.001]
  • [Cites] Microb Pathog. 1997 Oct;23(4):211-23 [9344782.001]
  • [Cites] Infect Immun. 1997 Nov;65(11):4813-21 [9353070.001]
  • [Cites] Infect Immun. 1998 Sep;66(9):4545-8 [9712817.001]
  • [Cites] Mol Microbiol. 1998 Aug;29(3):915-29 [9723929.001]
  • [Cites] Infect Immun. 1998 Dec;66(12):5755-62 [9826351.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52 [9841674.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1920-3 [10489373.001]
  • [Cites] J Bacteriol. 1963 Jul;86:101-11 [14051801.001]
  • [Cites] Infect Immun. 2004 Dec;72(12):7212-9 [15557646.001]
  • [Cites] Curr Opin Microbiol. 2005 Feb;8(1):21-7 [15694853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17786-91 [16306265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5526-30 [16567636.001]
  • [Cites] FEMS Microbiol Lett. 2006 Sep;262(2):158-62 [16923070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13514-9 [16938880.001]
  • [Cites] Science. 2007 Jan 26;315(5811):509-13 [17255510.001]
  • [Cites] Infect Immun. 2007 Mar;75(3):1272-9 [17178780.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2941-51 [17768237.001]
  • [Cites] Adv Exp Med Biol. 2007;603:97-105 [17966407.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):612-22 [18025094.001]
  • [Cites] Infect Immun. 1988 Oct;56(10):2749-52 [2843471.001]
  • [Cites] Microb Pathog. 1987 Oct;3(4):239-48 [3504547.001]
  • [Cites] Infect Immun. 1989 Apr;57(4):1200-10 [2925246.001]
  • (PMID = 20679446.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2950350
  •  go-up   go-down


45. Pernthaner A, Shaw RJ, McNeill MM, Morrison L, Hein WR: Total and nematode-specific IgE responses in intestinal lymph of genetically resistant and susceptible sheep during infection with Trichostrongylus colubriformis. Vet Immunol Immunopathol; 2005 Mar 10;104(1-2):69-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total and antigen-specific IgE responses in afferent (AIL) and efferent (EIL) intestinal lymph of sheep with a nematode resistant (R) or susceptible (S) genotype during challenge infection with the intestinal nematode parasite Trichostrongylus colubriformis were examined.
  • Total IgE level in AIL and EIL was dependent on nematode infection and was further influenced by genotype or the immune phenotype (nematode immune mean FEC+/-SDM=77+/-179 or non-immune mean FEC+/-SDM=4016+/-4318) of the animal.
  • Concentrations of total IgE were consistently higher in AIL than EIL or serum and were higher in lymph draining the proximal than the distal jejunum demonstrating that polyclonal IgE in AIL was largely derived from the intestinal mucosa of the anatomical compartment where the nematodes reside.
  • The consistently higher concentration of total IgE in AIL was dependent on phenotype or genotype and in S genotype sheep also on the pre-challenge status.
  • Concentrations of nematode specific IgE were significantly higher in EIL than AIL indicating a preference for the production of IgE reacting with excretory secretory products of the infective T. colubriformis larvae in the regional lymph node.
  • [MeSH-minor] Animals. Antibodies, Helminth / analysis. Antibodies, Helminth / immunology. Antibody Specificity. Blotting, Western / veterinary. Enzyme-Linked Immunosorbent Assay / veterinary. Feces / parasitology. Female. Genetic Predisposition to Disease. Lymph / immunology. Lymph / parasitology. Male. Parasite Egg Count / veterinary. Sheep

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661332.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


46. Hegarty A, Georgakopolou E, Porter S: Bisphosphonate-related osteochemonecrosis of the jaws. Br J Hosp Med (Lond); 2008 Mar;69(3):158-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIl doctors prescribing bisphosphonates have a responsibility to patients to inform them of the risks of this complication no matter how small.

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422225.001).
  • [ISSN] 1750-8460
  • [Journal-full-title] British journal of hospital medicine (London, England : 2005)
  • [ISO-abbreviation] Br J Hosp Med (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  • [Number-of-references] 30
  •  go-up   go-down


47. Pradeep TG, Cannon P, Dodd T, Selva D: Lacrimal gland involvement in lymphomatoid granulomatosis and review of the literature. J Ophthalmol; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lacrimal gland involvement in lymphomatoid granulomatosis and review of the literature.
  • Objective. To describe the clinicoradiological and histopathological findings in a case of lacrimal gland enlargement secondary to lymphomatoid granulomatosis (LG) and to review the literature.
  • She subsequently developed pulmonary symptoms and underwent transbronchial biopsy that was diagnosed as LG.
  • Pub Med and OVID databases were searched using the term "orbit/eye involvement in lymphomatoid granulomatosis".
  • Results. The patient underwent lacrimal gland biopsy which revealed necrotic and inflamed tissue with no further categorisation but transbronchial biopsy helped in establishing the diagnosis of LG.
  • On initiation of prednisolone and cyclophosphamide, her orbital lesion resolved but the patient died following massive pulmonary hemorrhage within a month of diagnosis.
  • Conclusion. Ophthalmic involvement in LG is very rare.
  • LG is an angiocentric and angiodestructive granulomatous disorder and can involve any tissue, thus accounting for the variable presentations reported in literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871660.001).
  • [ISSN] 2090-0058
  • [Journal-full-title] Journal of ophthalmology
  • [ISO-abbreviation] J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2939439
  •  go-up   go-down


48. Chen J, Li GL, Liu P, Que CL, Wang GF: [A case report of lymphomatoid granulomatosis and review of the literature]. Beijing Da Xue Xue Bao; 2009 Aug 18;41(4):484-6
Genetic Alliance. consumer health - Lymphomatoid granulomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of lymphomatoid granulomatosis and review of the literature].
  • To explore the clinical manifestation of lymphomatoid granulomatosis (LG) and the early diagnosis.
  • Retrospective analyses of the clinical features of LG and pathology features by open lung biopsies were conducted.
  • Open lung biopsy proved LG.
  • LG is seldom seen in clinic.
  • Open lung biopsy is very important for pathology diagnosis.
  • Early diagnosis and treatment are the key to improving survival in these patients.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Lung / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727244.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Suzuki H, Takeda H, Kishi H, Machida Y, Mikura S, Watanabe K: [Reactivation of Epstein-Barr virus is involved in the pathogenesis of lymphomatoid granulomatosis]. Nihon Kokyuki Gakkai Zasshi; 2006 Jul;44(7):492-8
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reactivation of Epstein-Barr virus is involved in the pathogenesis of lymphomatoid granulomatosis].
  • Recent studies point to a role of Epstein-Barr virus in the pathogenesis of lymphomatoid granulomatosis.
  • Little is however known about the association of the pathogenesis of the disease with Epstein-Barr virus reactivation.
  • He died of rapidly progressive neurological lesions.
  • The definitive diagnosis of lymphomatoid granulomatosis was made from histological findings of the surgical biopsy specimen and at autopsy.
  • This result suggests that reactivation of Epstein-Barr virus is involved in the development of the disease.
  • [MeSH-major] Herpesvirus 4, Human / physiology. Lung Diseases / etiology. Lung Diseases / virology. Lymphomatoid Granulomatosis / etiology. Lymphomatoid Granulomatosis / virology. Virus Activation

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886805.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


50. Bowman AS, Glendening C, Wittum TE, LeJeune JT, Stich RW, Funk JA: Prevalence of Yersinia enterocolitica in different phases of production on swine farms. J Food Prot; 2007 Jan;70(1):11-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presumptive isolates were confirmed as YE and assayed for the presence of ail with a multiplex PCR.
  • Of the 2,349 pigs sampled, 120 (5.1%) tested positive, and of those, 51 were ail positive (42.5% of YE isolates).
  • Only 1.4% (44.4% of which were ail positive) of nursery pigs tested positive, but 10.7% (48.1% of which were ail positive) of finishing pigs harbored YE.
  • Interestingly, gestating sows had the second highest prevalence of YE at 9.1% (26.7% of which were ail positive), yet YE was never detected from the farrowing sows.
  • [MeSH-minor] Aging / physiology. Animals. Cross-Sectional Studies. Disease Reservoirs / microbiology. Disease Reservoirs / veterinary. Feces / microbiology. Female. Food Contamination / analysis. Food Contamination / prevention & control. Humans. Male. Polymerase Chain Reaction / methods. Polymerase Chain Reaction / veterinary. Pregnancy. Prevalence. Swine. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265853.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial
  •  go-up   go-down


51. Bhaduri S, Wesley I: Isolation and characterization of Yersinia enterocolitica from swine feces recovered during the National Animal Health Monitoring System Swine 2000 study. J Food Prot; 2006 Sep;69(9):2107-12
MedlinePlus Health Information. consumer health - Bowel Movement.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The isolates were confirmed as pathogenic Y. enterocolitica by the fluorogenic 5' nuclease PCR assay targeting the chromosomal attachment invasion ail gene.
  • Of 2793 fecal samples tested, 106 (3.80%) ail-positive strains of Y. enterocolitica were isolated.
  • These 106 ail-positive isolates originated from 7 of the 15 participating states.
  • [MeSH-minor] Animals. Colony Count, Microbial. Consumer Product Safety. Culture Media / chemistry. Disease Reservoirs / veterinary. Food Contamination / analysis. Food Contamination / prevention & control. Food Microbiology. Humans. Prevalence. Serotyping. Virulence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995512.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media
  •  go-up   go-down


52. Anel L, Kaabi M, Abroug B, Alvarez M, Anel E, Boixo JC, de la Fuente LF, de Paz P: Factors influencing the success of vaginal and laparoscopic artificial insemination in churra ewes: a field assay. Theriogenology; 2005 Mar 1;63(4):1235-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this work we studied the influence of many factors on the fertility of the Churra breed (insemination technique, year, farm, age, male, number of inseminations per ewe, lambing-insemination interval and technician), analyzing lambing data obtained after 44448 inseminations (39.67% cervical AI via vagina, AIV, and 60.33% intrauterine AI using laparoscopy, AIL) in a categorical model.
  • AIL showed significantly higher fertility results than AIV (44.89% versus 31.25%).
  • Fertility dropped 1.74% (AIV) and 2.07% (AIL) per year as the ewes aged.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710206.001).
  • [ISSN] 0093-691X
  • [Journal-full-title] Theriogenology
  • [ISO-abbreviation] Theriogenology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Seifried C, Weidauer S, Hinsch N, Bug R, Steinmetz H: [Cerebral lymphomatoid granulomatosis. A case report]. Nervenarzt; 2007 Feb;78(2):193-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebral lymphomatoid granulomatosis. A case report].
  • [Transliterated title] Zerebrale lymphomatoide Granulomatose. Ein Fallbericht.
  • MR imaging revealed multiple lesions, particularly in the subcortical white matter, with spot like central contrast enhancement.
  • The diagnosis of lymphomatoid granulomatosis was finally made through open lung biopsy.
  • Despite treatment with rituximab and, in the later course of the disease, additionally with cyclophosphamide, the patient died 3 months after the diagnosis was made.
  • [MeSH-major] Brain Neoplasms / complications. Confusion / etiology. Fever of Unknown Origin / etiology. Lymphomatoid Granulomatosis / complications. Magnetic Resonance Imaging. Radiography, Thoracic. Tomography, X-Ray Computed


54. Fawcett GL, Roseman CC, Jarvis JP, Wang B, Wolf JB, Cheverud JM: Genetic architecture of adiposity and organ weight using combined generation QTL analysis. Obesity (Silver Spring); 2008 Aug;16(8):1861-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present here a detailed study of the genetic contributions to adult body size and adiposity in the LG,SM advanced intercross line (AIL), an obesity model.
  • This study represents a first step in fine-mapping obesity quantitative trait loci (QTLs) in an AIL.
  • We analyzed both the F(2) and F(3) generations of the LG,SM AIL population single-nucleotide polymorphism (SNP) genotyped with a marker density of approximately 4 cM.
  • We present a relatively rapid means to obtain fine-mapping details from AILs using dense marker maps and consecutive generations.

  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551125.001).
  • [ISSN] 1930-7381
  • [Journal-full-title] Obesity (Silver Spring, Md.)
  • [ISO-abbreviation] Obesity (Silver Spring)
  • [Language] ENG
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C516936/1; United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C/516936; United States / NIDDK NIH HHS / DK / DK 055736
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Zhang S, Lou Y, Amstein TM, Anyango M, Mohibullah N, Osoti A, Stancliffe D, King R, Iraqi F, Gershenfeld HK: Fine mapping of a major locus on chromosome 10 for exploratory and fear-like behavior in mice. Mamm Genome; 2005 May;16(5):306-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced intercross lines (AIL) and interval-specific congenic strains (ISCS) were used to fine map previously coarsely defined quantitative trait loci (QTL) on Chromosomes 1, 10, and 19, influencing behaviors in the open Field (OF) and light-dark (LD) paradigms in mice.
  • F12(A x B) AIL mice (N = 1130) were phenotyped, genotyped, and mapped.
  • The Chromosome 10 Exq1 and Chromosome 19 Exq4 loci mapped robustly in the AIL.
  • The replicated QTLs on Chromosome 1 failed to map in this AIL population.

  • COS Scholar Universe. author profiles.
  • GeneWeaver. GeneWeaver .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104379.001).
  • [ISSN] 0938-8990
  • [Journal-full-title] Mammalian genome : official journal of the International Mammalian Genome Society
  • [ISO-abbreviation] Mamm. Genome
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / R01-MH58882
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Genetic Markers
  •  go-up   go-down


56. Hammer N, Steinke H, Böhme J, Stadler J, Josten C, Spanel-Borowski K: Description of the iliolumbar ligament for computer-assisted reconstruction. Ann Anat; 2010 May 20;192(3):162-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: A macroscopic study was performed to measure the anterior (AIL) and the posterior part of the IL (PIL).
  • METHODS: Frozen sections prepared from 29 human subjects were measured and 7-tesla MR images made to distinguish the AIL and PIL.
  • Lengths of 30 and 25 mm were measured for the AIL and PIL, as well as heights of 17-19 mm, respectively, and a thickness of 4mm.
  • CONCLUSIONS: Correlations between the side-dependent parameters and the AIL and the PIL of the same side indicate close functional relationships.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier GmbH.
  • (PMID = 20382512.001).
  • [ISSN] 1618-0402
  • [Journal-full-title] Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
  • [ISO-abbreviation] Ann. Anat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


57. Biedzka-Sarek M, Jarva H, Hyytiäinen H, Meri S, Skurnik M: Characterization of complement factor H binding to Yersinia enterocolitica serotype O:3. Infect Immun; 2008 Sep;76(9):4100-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another OM protein, Ail, also contributes to FH binding provided that it is not blocked by distal parts of the lipopolysaccharide (i.e., the O antigen and the outer core hexasaccharide).
  • Importantly, we demonstrated that surface-bound FH was functional; both YadA- and Ail-bound FH displayed cofactor activity for factor I-mediated cleavage of C3b.
  • With truncated recombinant FH constructs, we located the binding site of Ail specifically to short consensus repeats 6 and 7 of FH, while YadA showed a novel type of FH-binding pattern and appears to bind FH throughout the entire FH molecule.
  • We thus conclude that Y. enterocolitica, via YadA and Ail, recruits functionally active FH to its surface.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Microbiol. 1995 Aug;17(3):575-94 [8559076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1657-61 [2964038.001]
  • [Cites] Eur J Immunol. 1996 Oct;26(10):2383-7 [8898949.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5422-7 [8955190.001]
  • [Cites] Clin Microbiol Rev. 1997 Apr;10(2):257-76 [9105754.001]
  • [Cites] J Exp Med. 1998 Mar 2;187(5):743-52 [9480984.001]
  • [Cites] EMBO J. 2000 Nov 15;19(22):5989-99 [11080146.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8427-35 [11113124.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(5):1053-62 [11555286.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1886-94 [11823523.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12642-8 [11812795.001]
  • [Cites] Infect Immun. 2002 Sep;70(9):5185-92 [12183569.001]
  • [Cites] J Bacteriol. 2003 Jul;185(13):3735-44 [12813066.001]
  • [Cites] J Immunol. 1995 Jul 1;155(1):348-56 [7541419.001]
  • [Cites] Gene. 1995 Sep 11;162(2):225-9 [7557433.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5663-70 [7499851.001]
  • [Cites] Infect Immun. 1988 May;56(5):1242-8 [2833444.001]
  • [Cites] Mol Microbiol. 1989 Apr;3(4):517-29 [2761389.001]
  • [Cites] Complement Inflamm. 1989;6(4):270-80 [2527715.001]
  • [Cites] J Bacteriol. 1989 Dec;171(12):6674-9 [2592347.001]
  • [Cites] J Bacteriol. 1990 Feb;172(2):1062-9 [1688838.001]
  • [Cites] J Bacteriol. 1990 Jun;172(6):3152-62 [2160939.001]
  • [Cites] Nature. 1990 Aug 30;346(6287):871-4 [2144037.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):156-60 [1987115.001]
  • [Cites] J Bacteriol. 1991 Jan;173(1):86-93 [1846140.001]
  • [Cites] Microb Pathog. 1991 Jan;10(1):47-59 [1857198.001]
  • [Cites] Microb Pathog. 1991 Jan;10(1):81-6 [1857201.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16847-53 [1832158.001]
  • [Cites] Infect Immun. 1992 Jan;60(1):189-95 [1729182.001]
  • [Cites] J Bacteriol. 1992 Jan;174(1):84-91 [1729227.001]
  • [Cites] J Bacteriol. 1992 Feb;174(4):1360-9 [1370953.001]
  • [Cites] Infect Immun. 1992 Mar;60(3):870-5 [1311707.001]
  • [Cites] J Bacteriol. 1992 Mar;174(6):2047-51 [1548243.001]
  • [Cites] Mol Microbiol. 1992 Feb;6(3):395-409 [1552853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3561-5 [1565652.001]
  • [Cites] Infect Immun. 1992 Oct;60(10):3986-93 [1398910.001]
  • [Cites] Infect Immun. 1993 Aug;61(8):3129-36 [8335343.001]
  • [Cites] Infect Immun. 1994 Apr;62(4):1252-61 [8132332.001]
  • [Cites] Infect Immun. 1994 Nov;62(11):5183-6 [7927803.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3342-8 [9531293.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3349-54 [9531294.001]
  • [Cites] J Exp Med. 1998 Aug 17;188(4):671-80 [9705949.001]
  • [Cites] Mol Microbiol. 1999 Mar;31(5):1443-62 [10200964.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2232-44 [15784567.001]
  • [Cites] Infect Immun. 2003 Dec;71(12):7119-28 [14638802.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2421-9 [14607842.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3111-8 [14978117.001]
  • [Cites] J Exp Med. 1976 Nov 2;144(5):1147-63 [62817.001]
  • [Cites] J Exp Med. 1977 Jul 1;146(1):257-70 [301546.001]
  • [Cites] Nature. 1980 Jan 10;283(5743):224-6 [7350546.001]
  • [Cites] Infect Immun. 1980 Feb;27(2):682-5 [7380546.001]
  • [Cites] Nucleic Acids Res. 1981 Jan 24;9(2):309-21 [6259625.001]
  • [Cites] Infect Immun. 1981 Sep;33(3):870-6 [7287174.001]
  • [Cites] Anal Biochem. 1981 Oct;117(1):136-46 [7316186.001]
  • [Cites] J Gen Microbiol. 1983 Sep;129(9):2739-47 [6195308.001]
  • [Cites] J Appl Bacteriol. 1984 Jun;56(3):355-63 [6146593.001]
  • [Cites] EMBO J. 1985 Apr;4(4):1013-8 [4018036.001]
  • [Cites] J Immunol. 1986 May 1;136(9):3407-11 [2937845.001]
  • [Cites] Clin Exp Immunol. 1987 May;68(2):266-74 [3652518.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2506-14 [8698473.001]
  • (PMID = 18625735.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / YadA protein, Yersinia; 80295-65-4 / Complement Factor H
  • [Other-IDs] NLM/ PMC2519436
  •  go-up   go-down


58. Siddique N, Sharma D, Al-Khaldi SF: Detection of Yersinia enterocolitica in alfalfa, mung bean, cilantro, and mamey sapote (Pouteria sapota) food matrices using DNA microarray chip hybridization. Curr Microbiol; 2009 Sep;59(3):233-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The amplified DNA was used as templates in single PCR reactions of the four genes (virF, ail, yst, and blaA) followed by mixing the four reactions for one PCR primer extension reaction.
  • Ail was detected in 10(3) cfu/g, whereas blaA and yst were detected from 10(5) to 10(6) cfu/g in all food matrices.
  • Therefore, the ail gene could be the gene of choice in identifying Y. enterocolitica in alfalfa, cilantro, mamey, and mung bean.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504157.001).
  • [ISSN] 1432-0991
  • [Journal-full-title] Current microbiology
  • [ISO-abbreviation] Curr. Microbiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Ragage F, Parrens M, Banos A, Renoux M, Bégueret H, Merlio JP, de Mascarel A: [Lymphomatoid granulomatosis after treatment of an acute myeloid leukemia]. Ann Pathol; 2006 Feb;26(1):22-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomatoid granulomatosis after treatment of an acute myeloid leukemia].
  • [Transliterated title] Granulomatose lymphomatoïde dans les suites d'une leucémie aiguë myéloïde.
  • We report a case of lymphomatoid granulomatosis (LG), arising in a 60-year-old man in the setting of an acute myeloid leukemia.
  • LG is a rare Epstein Barr virus (EBV) lymphoproliferative disorder, generally occurring in a context of immunodeficiency.
  • Histologically LG is characterized by an angiocientric and angiodestructive lymphoproliferation of B/EBV+ cells admixed with numerous reactive T cells.
  • The differential diagnosis mainly includes pulmonary vasculitis and Hodgkin's lymphoma.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Lymphomatoid Granulomatosis / pathology
  • [MeSH-minor] Antigens, CD / analysis. Biopsy. Diagnosis, Differential. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Nuclear Antigens / analysis. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841006.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Epstein-Barr Virus Nuclear Antigens
  •  go-up   go-down


60. Jaffre S, Jardin F, Dominique S, Duet E, Hubscher P, Genevois A, Corne F, Bota S, Nouvet G, Thiberville L: Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab. Eur Respir J; 2006 Mar;27(3):644-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab.
  • Lymphomatoid granulomatosis is a rare angiocentric and angiodestructive disease, which commonly involves the lungs but also the brain, kidneys, liver and skin.
  • This report describes the case of a 33-yr-old female with an aggressive form of lymphoid granulomatosis treated with an anti-CD20 antibody.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hemoptysis / etiology. Immunologic Factors / therapeutic use. Lymphomatoid Granulomatosis / complications. Lymphomatoid Granulomatosis / drug therapy

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507866.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


61. Brignole C, Marimpietri D, Pastorino F, Di Paolo D, Pagnan G, Loi M, Piccardi F, Cilli M, Tradori-Cappai A, Arrigoni G, Pistoia V, Ponzoni M: Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides. J Control Release; 2009 Sep 1;138(2):122-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In principle, combination of TL-asCpG and antibodies against IL-10 receptor (aIL-10R) could prolong immune system activation, leading to better therapeutic results.
  • The addition of aIL-10R to TL-asCpG in the 4-h protocol significantly increased the percentage of long term survivors compared to TL-asCpG only.
  • TL-asCpG plus aIL-10R treatment was significantly superior to TL-asCpG alone also for the 24-h protocol.
  • These results support the feasibility of a clinical trial with TL-asCpG and aIL-10R in advanced NB patients.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427884.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gangliosides; 0 / Liposomes; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-myb; 0 / Receptors, Interleukin-10; 130068-27-8 / Interleukin-10; 65988-71-8 / ganglioside, GD2
  •  go-up   go-down


62. Dambe R, Hähnel S, Heiland S: Measuring anisotropic brain diffusion in three and six directions: influence of the off-diagonal tensor elements. Neuroradiol J; 2007 Feb 28;20(1):18-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We then calculated the diffusion trace and the linear anisotropy index (AIl).
  • We measured a slight anisotropy in the phantoms, which was larger in the case of the full tensor DTI (AIl = 0.022) then for the three orthogonal diffusion directions (0.008-0.019).
  • AIl values were moderately correlated between right and left hemisphere regions (correlation factor: 0.35-0.64).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24299583.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Halvani A, Owlia MB, Sami R: Lymphomatoid granulomatosis with splenomegaly and pancytopenia. Zhongguo Fei Ai Za Zhi; 2010 Jan;13(1):84-6
Genetic Alliance. consumer health - Splenomegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis with splenomegaly and pancytopenia.
  • Lymphomatoid granulomatosis (LG) is an angiocentric lymphoproliferative disease.
  • It usually involves lung, skin, and central nervous system, but splenomegaly and pancytopenia are the rare manifestations of the disease.
  • We report a 15-year-old boy presented with fever, dry cough and dyspnea from two months ago, after admission patient had nodular lesions on the left leg and hepatosplenomegaly.
  • Skin biopsy was done, and histopathological examination and immunohistochemistry evaluation confirmed lymphomatoid granulomatosis.
  • [MeSH-major] Lymphomatoid Granulomatosis / diagnosis. Pancytopenia / diagnosis. Splenomegaly / diagnosis

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672711.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Gupta T, Wadasadawala T, Shet T, Jalali R, Menon H: Isolated central nervous system involvement by lymphomatoid granulomatosis in an adolescent: a case report and review of literature. Pediatr Hematol Oncol; 2010 Mar;27(2):150-9
Genetic Alliance. consumer health - Lymphomatoid granulomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system involvement by lymphomatoid granulomatosis in an adolescent: a case report and review of literature.
  • Lymphomatoid granulomatosis is an Epstein-Barr virus-associated multisystem disease that combines granulomatous inflammatory process with lymphoproliferative potential.
  • It predominantly affects lungs, skin, and brain and is characterized by multifocal, transmural, angiocentric, and angiodestructive pleomorphic lymphoid infiltrate in a perivascular distribution.
  • Lymphomatoid granulomatosis is generally considered to be a neoplastic B-cell proliferation that has traditionally been associated with poor prognosis, evolving as a progressive multisystem disease transforming into B-cell lymphoma, with a median survival of 14 to 16 months only.
  • Neuroimaging showed 2 space-occupying lesions, larger in the left frontoparietal region with heterogeneous enhancement, moderate perifocal edema, compression, and mass effect.
  • He underwent surgical decompression of the dominant lesion with prompt relief of symptoms.
  • The diagnosis of lymphomatoid granulomatosis was confirmed on light microscopy and immunohistochemistry.
  • Awareness of disease spectrum in the central nervous system may permit early diagnosis and thus allow institution of timely appropriate therapy.
  • [MeSH-major] Central Nervous System / pathology. Central Nervous System / physiopathology. Lymphomatoid Granulomatosis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201696.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 23
  •  go-up   go-down


65. Schmitt AO, Bortfeldt R, Neuschl C, Brockmann GA: RandoMate: a program for the generation of random mating schemes for small laboratory animals. Mamm Genome; 2009 May;20(5):321-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced intercross lines (AIL) have proven to be a powerful tool in genetic research to map complex genetic traits.
  • The advantage of AIL is the high enrichment of visible recombination events to fine map the position of the target gene.
  • Therefore, AIL are generated under the avoidance of inbreeding.
  • RandoMate is freely available at http://www2.hu-berlin.de/RandoMate .

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444508.001).
  • [ISSN] 1432-1777
  • [Journal-full-title] Mammalian genome : official journal of the International Mammalian Genome Society
  • [ISO-abbreviation] Mamm. Genome
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Lambertz ST, Nilsson C, Hallanvuo S: TaqMan-based real-time PCR method for detection of Yersinia pseudotuberculosis in food. Appl Environ Microbiol; 2008 Oct;74(20):6465-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primer-probe set was designed to target a 157-bp sequence of the chromosomally located gene ail.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3541-7 [11574570.001]
  • [Cites] Methods Mol Biol. 2003;216:51-64 [12512355.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1810-6 [12620874.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5134-46 [14605150.001]
  • [Cites] J Infect Dis. 2004 Mar 1;189(5):766-74 [14976592.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2789-91 [15184472.001]
  • [Cites] Infect Immun. 1989 Jan;57(1):121-31 [2642465.001]
  • [Cites] Contrib Microbiol Immunol. 1995;13:153-5 [8833821.001]
  • [Cites] J Vet Med Sci. 1997 Mar;59(3):153-8 [9101473.001]
  • [Cites] J Clin Microbiol. 1998 Sep;36(9):2557-64 [9705392.001]
  • [Cites] Appl Environ Microbiol. 2005 Jul;71(7):3674-81 [16000776.001]
  • [Cites] J Infect Dis. 2006 Nov 1;194(9):1209-16 [17041846.001]
  • [Cites] J Food Prot. 2007 Feb;70(2):335-40 [17340866.001]
  • [Cites] Appl Environ Microbiol. 2007 Mar;73(6):1892-8 [17259359.001]
  • [Cites] Appl Environ Microbiol. 2008 Oct;74(19):6060-7 [18708521.001]
  • [Cites] Epidemiol Infect. 2009 Mar;137(3):342-7 [18177523.001]
  • (PMID = 18757572.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  • [Other-IDs] NLM/ PMC2570298
  •  go-up   go-down


67. Zhou H, Lamont SJ: Global gene expression profile after Salmonella enterica Serovar enteritidis challenge in two F8 advanced intercross chicken lines. Cytogenet Genome Res; 2007;117(1-4):131-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two F8 advanced intercross lines (AIL), broiler by Leghorn, and broiler by Fayoumi, were studied.
  • The 20% high and 20% low SE burden birds within each AIL and harvest time were studied by microarray.
  • The loop design was used for pair-comparison between high and low SE burden challenged birds and unchallenged birds, within each AIL and harvest time.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17675853.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Samocha KE, Lim JE, Cheng R, Sokoloff G, Palmer AA: Fine mapping of QTL for prepulse inhibition in LG/J and SM/J mice using F(2) and advanced intercross lines. Genes Brain Behav; 2010 Oct;9(7):759-67
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine mapping of QTL for prepulse inhibition in LG/J and SM/J mice using F(2) and advanced intercross lines.
  • Humans with neurological and psychiatric disorders, including schizophrenia, obsessive-compulsive disorder and Huntington's disease, exhibit a reduction in PPI.
  • In order to elucidate the genes involved in sensorimotor gating, we phenotyped 472 mice from an F(2) cross between LG/J × SM/J for PPI and genotyped these mice genome-wide using 162 single nucleotide polymorphism (SNP) markers.
  • We also phenotyped 135 mice from an F(34) advanced intercross line (AIL) between LG/J × SM/J for PPI and genotyped them at more than 3000 SNP markers.
  • Inclusions of data from the AIL mice reduced the size of several of these QTLs to less than 5 cM.
  • These results will be useful for identifying genes that influence sensorimotor gaiting and show the power of AIL for fine mapping of QTLs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Genes, Brain and Behavior © 2010 Blackwell Publishing Ltd and International Behavioural and Neural Genetics Society.
  • [Cites] Biol Psychiatry. 1993 Feb 15;33(4):298-301 [8471686.001]
  • [Cites] Arch Gen Psychiatry. 1992 Mar;49(3):206-15 [1567275.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Br J Med Psychol. 1961;34:103-16 [13773940.001]
  • [Cites] Biol Psychiatry. 2005 May 15;57(10):1153-8 [15866555.001]
  • [Cites] Genet Res. 2005 Jun;85(3):211-22 [16174340.001]
  • [Cites] Genetics. 2005 Dec;171(4):1895-904 [15998716.001]
  • [Cites] Heredity (Edinb). 1992 Oct;69(4):315-24 [16718932.001]
  • [Cites] Arch Gen Psychiatry. 2007 Nov;64(11):1242-50 [17984393.001]
  • [Cites] PLoS Biol. 2007 Nov;5(11):e297 [18001149.001]
  • [Cites] Biol Psychiatry. 2007 Dec 15;62(12):1418-22 [17481589.001]
  • [Cites] Pharmacol Biochem Behav. 2008 Oct;90(4):525-33 [18513787.001]
  • [Cites] Biol Psychiatry. 2009 Mar 1;65(5):401-8 [19013555.001]
  • [Cites] Schizophr Res. 2009 Jun;111(1-3):182-91 [19351577.001]
  • [Cites] Neurosci Res. 2009 Nov;65(3):259-62 [19660506.001]
  • [Cites] Genes Brain Behav. 2009 Nov;8(8):806-16 [19694817.001]
  • [Cites] Genetics. 2010 Jul;185(3):1033-44 [20439773.001]
  • [Cites] Behav Neurosci. 2000 Apr;114(2):374-88 [10832798.001]
  • [Cites] Am J Psychiatry. 2000 Oct;157(10):1660-8 [11007721.001]
  • [Cites] Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54 [11549216.001]
  • [Cites] Biol Psychiatry. 2001 Sep 15;50(6):418-24 [11566158.001]
  • [Cites] Genome Res. 2002 Apr;12(4):618-26 [11932246.001]
  • [Cites] Neuropsychopharmacology. 2002 Nov;27(5):765-81 [12431851.001]
  • [Cites] Psychopharmacology (Berl). 2003 Jan;165(3):270-9 [12426667.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Behav Neurosci. 2003 Aug;117(4):716-27 [12931957.001]
  • [Cites] J Neurosci Res. 2003 Nov 15;74(4):562-9 [14598300.001]
  • [Cites] Neurosci Lett. 2003 Dec 15;353(1):45-8 [14642434.001]
  • [Cites] Psychopharmacology (Berl). 2004 Aug;174(4):452-62 [15300359.001]
  • [Cites] Genome Res. 2004 Sep;14(9):1806-11 [15342563.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):192-200 [7876851.001]
  • (PMID = 20597988.001).
  • [ISSN] 1601-183X
  • [Journal-full-title] Genes, brain, and behavior
  • [ISO-abbreviation] Genes Brain Behav.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / T32 MH020065; United States / NIMH NIH HHS / MH / R01 MH079103; United States / NIDA NIH HHS / DA / R01 DA021336; United States / NIDA NIH HHS / DA / R21DA024845; United States / NIDA NIH HHS / DA / R01DA021336; United States / NIMH NIH HHS / MH / T32MH020065; United States / NIDA NIH HHS / DA / R21 DA024845
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ NIHMS490035; NLM/ PMC3749925
  •  go-up   go-down


69. Carvalho RC, Fukushiro DF, Helfer DC, Callegaro-Filho D, Trombin TF, Zanlorenci LH, Sanday L, Silva RH, Frussa-Filho R: Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. Addict Biol; 2009 Jul;14(3):283-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compared the effects of withdrawal from long-term administration of the typical neuroleptic haloperidol (Hal) and/or the atypical agent risperidone (Ris) on MDS and NDS, behaviorally evaluated by amphetamine-induced locomotor stimulation (AILS) and apomorphine-induced stereotypy (AIS) in mice, respectively.
  • ) (but not 0.5 mg/kg Ris i.p.) treatment potentiated both AILS and AIS.
  • Ris co-administration abolished the potentiation of AILS and AIS observed in Hal-withdrawn mice.
  • Ten days after withdrawal from long-term treatment with Hal (but not with Ris or Ris + Hal), a potentiation in AILS was still observed.

  • Hazardous Substances Data Bank. RISPERIDONE .
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. APOMORPHINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298320.001).
  • [ISSN] 1369-1600
  • [Journal-full-title] Addiction biology
  • [ISO-abbreviation] Addict Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Dopamine Agonists; 0 / Dopamine D2 Receptor Antagonists; 0 / Receptors, Dopamine D2; J6292F8L3D / Haloperidol; L6UH7ZF8HC / Risperidone; N21FAR7B4S / Apomorphine
  •  go-up   go-down


70. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol; 2005 May;129(3):366-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The World Health Organization (WHO) lymphoma classification recognises anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoma (AIL) and peripheral T-cell lymphoma, unspecified (PTCU) as nodal mature T-cell lymphomas.
  • A retrospective analysis on 125 patients with ALCL, AIL or PTCU was performed to evaluate outcome parameters, taking into account histological subtype and the International Prognostic Index (IPI).
  • Five-year OS was 61% for ALCL, 45% for PTCU and 28% for AIL.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Transplantation. Cause of Death. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842660.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Tavazzi E, Bargiggia V, Pichiecchio A, Delbue S, Maserati R, Bastianello S, Ferrante P, Minoli L, Ricevuti G, Ceroni M, Marchioni E: HIV-related acute inflammatory leukoencephalopathy of undetermined origin: review of the literature. Int J Immunopathol Pharmacol; 2010 Jul-Sep;23(3):693-700
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-related acute inflammatory leukoencephalopathy of undetermined origin (AIL) has been anecdotally described in literature as being responsible for cognitive and motor deficits.
  • We carried out a review of all the cases of AIL published in literature.
  • Although rare (21 patients out of about 4,000 publications), AIL is of particular interest, as the comprehension of its mechanisms could give some insight into the direct and immune-mediated actions of HIV within the brain.
  • [MeSH-minor] AIDS Dementia Complex / pathology. Acute Disease. Anti-HIV Agents / therapeutic use. Brain / pathology. HIV Seropositivity. Humans. Magnetic Resonance Imaging. Spinal Cord / pathology. Terminology as Topic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20943038.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Editorial; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


72. Bhagat N, Virdi JS: Distribution of virulence-associated genes in Yersinia enterocolitica biovar 1A correlates with clonal groups and not the source of isolation. FEMS Microbiol Lett; 2007 Jan;266(2):177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Virulence-associated genes viz. ail, virF, inv, myfA, ystA, ystB, ystC, tccC, hreP, fepA, fepD, fes, ymoA and sat were studied in 81 clinical and nonclinical strains of Y. enterocolitica biovar 1A by PCR amplification.
  • All strains lacked ail, virF, ystA and ystC genes.
  • The clonal groups A and B were differentiated previously based on rep (REP-/ERIC) - PCR genomic fingerprinting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233728.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY966878/ AY966879/ AY966880/ AY966881/ AY970513/ AY970514/ AY970515/ AY970518/ AY970519/ DQ144904/ DQ144905/ DQ144908/ DQ144909/ DQ144910/ DQ144911
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Kot B, Trafny EA, Jakubczak A: Application of multiplex PCR for monitoring colonization of pig tonsils by Yersinia enterocolitica, including biotype 1A, and Yersinia pseudotuberculosis. J Food Prot; 2007 May;70(5):1110-5
MedlinePlus Health Information. consumer health - Foodborne Illness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The assay was based on the amplification of the ail, inv, yadA, and ystB genes.
  • The PCR products, corresponding to the ail gene and the plasmid-borne yadA gene or only one product corresponding to the ail gene, were detected in Y. enterocolitica 4 biotype isolates.
  • The presence of at least one of the specific PCR amplification products of ail-, ystB-, yadA-, and inv-specific sequences was observed in 11 samples (13.75%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536668.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Nganga JK, Soller M, Iraqi FA: High resolution mapping of trypanosomosis resistance loci Tir2 and Tir3 using F12 advanced intercross lines with major locus Tir1 fixed for the susceptible allele. BMC Genomics; 2010 Jun 22;11:394
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Trypanosomosis is the most economically important disease constraint to livestock productivity in Africa.
  • Subsequently, using F6 C57BL/6J x A/J and C57BL/6J x BALB/cJ F6 advanced intercross lines (AIL), Tir1 was fine mapped to a confidence interval (CI) of less than 1 cM, while Tir2 and Tir3, were mapped within 5-12 cM.
  • RESULTS: In order to improve map resolutions of Tir2 and Tir3, an F12 C57BL/6J x A/J AIL population fixed for the susceptible alleles at Tir1 QTL was generated.
  • An F12 C57BL/6J x A/J AIL population, fixed for the resistant alleles at Tir1 QTL was also generated to provide an additional estimate of the gene effect of Tir1.
  • The AIL populations homozygous for the resistant and susceptible Tir1 alleles and the parental controls were challenged with T. congolense and followed for survival times over 180 days.
  • Mice from the two survival extremes of the F12 AIL population fixed for the susceptible alleles at Tir1 were genotyped with a dense panel of microsatellite markers spanning the Tir2 and Tir3 genomic regions and QTL mapping was performed.

  • GeneWeaver. GeneWeaver .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mamm Genome. 2000 Aug;11(8):645-8 [10920233.001]
  • [Cites] PLoS One. 2009;4(4):e5170 [19365556.001]
  • [Cites] J Neurosci. 2002 May 1;22(9):3730-8 [11978849.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7443-8 [12805560.001]
  • [Cites] Clin Exp Immunol. 1978 Apr;32(1):25-40 [307464.001]
  • [Cites] Res Vet Sci. 1978 Nov;25(3):399-400 [749094.001]
  • [Cites] Infect Immun. 1980 Mar;27(3):707-13 [7380550.001]
  • [Cites] Acta Trop. 1987 Mar;44(1):55-66 [2884840.001]
  • [Cites] Acta Trop. 1988 Dec;45(4):389-432 [2907267.001]
  • [Cites] Vet Parasitol. 1989 Jun;31(3-4):187-97 [2763442.001]
  • [Cites] Genetics. 1994 Nov;138(3):963-71 [7851788.001]
  • [Cites] Genetics. 1995 Mar;139(3):1421-8 [7768449.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Vet Immunol Immunopathol. 1996 Nov;54(1-4):239-43 [8988870.001]
  • [Cites] Mamm Genome. 1997 Mar;8(3):163-7 [9069114.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):194-6 [9171834.001]
  • [Cites] World Health Organ Tech Rep Ser. 1998;881:I-VI, 1-114 [10070249.001]
  • [Cites] Science. 1999 Jun 4;284(5420):1670-2 [10356397.001]
  • [Cites] J Exp Med. 2004 Dec 20;200(12):1605-12 [15596523.001]
  • [Cites] Heredity (Edinb). 1992 Oct;69(4):315-24 [16718932.001]
  • [Cites] Annu Rev Genet. 2000;34:653-686 [11092842.001]
  • (PMID = 20569426.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2898758
  •  go-up   go-down


75. Fredriksson-Ahomaa M, Stolle A, Stephan R: Prevalence of pathogenic Yersinia enterocolitica in pigs slaughtered at a Swiss abattoir. Int J Food Microbiol; 2007 Nov 1;119(3):207-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human yersiniosis is the third most common enteric disease after campylobacteriosis and salmonellosis in many European countries.
  • This work was conducted to study the frequency of ail-positive Y. enterocolitica in pigs slaughtered at a Swiss abattoir.
  • The prevalence rate of ail-positive Y. enterocolitica in pigs at slaughter was 88% and 34% with PCR and culture methods, respectively.
  • The 148 ail-positive isolates from the 72 culture-positive tonsils were bio-and serotyped.
  • However, pig was also shown to be a reservoir for ail-positive Y. enterocolitica belonging to bioserotypes 2/O:5,27 and 2/O:9, which were detected in 8% (6/72) and 1% (1/72) of the culture-positive samples, respectively.
  • Antimicrobial resistance testing of 77 ail-positive Y. enterocolitica isolates from 72 samples studied with disc-diffusion revealed that all strains were sensitive to cefotaxime, chloramphenicol, ciprofloxacin and tetracycline, which are antimicrobial agents used for treatment of human disease.
  • [MeSH-minor] Animals. Anti-Bacterial Agents / pharmacology. Disease Reservoirs / veterinary. Drug Resistance, Bacterial. Electrophoresis, Gel, Pulsed-Field. Food Contamination / analysis. Food Contamination / prevention & control. Genotype. Palatine Tonsil / microbiology. Polymerase Chain Reaction / methods. Prevalence. Risk Assessment. Serotyping. Swine Diseases / drug therapy. Swine Diseases / epidemiology. Swine Diseases / microbiology. Switzerland / epidemiology. Yersinia Infections / drug therapy. Yersinia Infections / epidemiology. Yersinia Infections / microbiology. Yersinia Infections / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727997.001).
  • [ISSN] 0168-1605
  • [Journal-full-title] International journal of food microbiology
  • [ISO-abbreviation] Int. J. Food Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Anti-Bacterial Agents; 0 / Bacterial Outer Membrane Proteins
  •  go-up   go-down


76. Benamore RE, Weisbrod GL, Hwang DM, Bailey DJ, Pierre AF, Lazar NM, Maimon N: Reversed halo sign in lymphomatoid granulomatosis. Br J Radiol; 2007 Aug;80(956):e162-6
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversed halo sign in lymphomatoid granulomatosis.
  • Lymphomatoid granulomatosis is a rare lymphoproliferative disorder which affects extranodal sites, most commonly lung.
  • We describe a case of histologically proven lymphomatoid granulomatosis in a patient who presented initially with the more typical nodular opacities, which subsequently progressed into the reversed halo sign.
  • [MeSH-major] Lung Diseases / radiography. Lymphomatoid Granulomatosis / radiography

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Radiol. 2007 Oct;80(958):849-50 [17959924.001]
  • (PMID = 17762047.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Kaur M, Singh K, Rup PJ, Kamboj SS, Singh J: Anti-insect potential of lectins from Arisaema species towards Bactrocera cucurbitae. J Environ Biol; 2009 Nov;30(6):1019-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total development period was found to be prolonged by 3.5 and 2.3 days in case of larvae fed on artificial diet containing A. intermedium (AIL) and A. wallichianum (AWL), respectively.
  • LC50 values calculated on the basis of adult emergence came out to be 32.8 and 29 microg ml(-1) for AIL and AWL, respectively.
  • The activity of acid phosphatase decreased significantly in larvae reared on diet containing LC50 of AIL, while in case of AWL significant decrease was observed only at 72 hr of treatment.
  • These results showed that AIL and AWL have promising anti-insect potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329399.001).
  • [ISSN] 0254-8704
  • [Journal-full-title] Journal of environmental biology
  • [ISO-abbreviation] J Environ Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Insecticides; 0 / Lectins
  •  go-up   go-down


78. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S: Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies. Neuropsychopharmacology; 2007 Jul;32(7):1540-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The comparison was carried out using: brain D(2) and 5-HT(2) receptor occupancy; animal models predictive of antipsychotic efficacy (amphetamine-induced hyperlocomotion (AIL) and conditioned avoidance response (CAR) models); measures predictive of side effects (catalepsy and prolactin elevation); and molecular markers predictive of antipsychotic action (striatal Fos induction).
  • In contrast to other antipsychotics, NDMC was not very effective in reducing AIL or CAR and showed minimal induction of Fos in the nucleus accumbens.

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. CLOZAPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164815.001).
  • [ISSN] 0893-133X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Biomarkers; 0 / Dopamine Agonists; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-fos; 0 / Quinolones; 0 / Receptors, Dopamine D2; 0 / Receptors, Serotonin, 5-HT2; 0 / Serotonin Antagonists; 6104-71-8 / norclozapine; 82VFR53I78 / Aripiprazole; 9002-62-4 / Prolactin; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol
  •  go-up   go-down


79. Bhaduri S, Wesley I, Richards H, Draughon A, Wallace M: Clonality and antibiotic susceptibility of Yersinia enterocolitica isolated from U.S. market weight hogs. Foodborne Pathog Dis; 2009 Apr;6(3):351-6
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study 106 ail-positive pathogenic Y. enterocolitica isolates, previously recovered from 2793 swine fecal samples (3.8%) collected during National Animal Health Monitoring System's Swine 2000 study, were examined.
  • The presence of the ail gene, virulence plasmid, the expression of virulence determinants, and serotypes indicate that these isolates from U.S. swine are potentially capable of causing human foodborne illness.

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278339.001).
  • [ISSN] 1556-7125
  • [Journal-full-title] Foodborne pathogens and disease
  • [ISO-abbreviation] Foodborne Pathog. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Outer Membrane Proteins; 0 / Virulence Factors; 0 / yopE protein, Yersinia
  •  go-up   go-down


80. Lewis S: Can a learning-disabled nation learn healthcare lessons from abroad? Healthc Policy; 2007 Nov;3(2):19-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The case made here is that we need to declare a moratorium on the sustainability debate, become more adept at learning which features of international systems we can and cannot easily import, and recognize that what ails our system originates in design rather than the laws of nature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CMAJ. 2004 Jun 8;170(12):1817-24 [15184339.001]
  • [Cites] JAMA. 2002 Nov 20;288(19):2449-57 [12435258.001]
  • [Cites] Med Care. 2006 Oct;44(10):929-35 [17001264.001]
  • [Cites] BMJ. 2002 Apr 6;324(7341):819-23 [11934775.001]
  • [Cites] BMJ. 2002 May 18;324(7347):1205-9 [12016191.001]
  • (PMID = 19305776.001).
  • [ISSN] 1715-6572
  • [Journal-full-title] Healthcare policy = Politiques de santé
  • [ISO-abbreviation] Healthc Policy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2645172
  •  go-up   go-down


81. Melegh Z, Sutak J, Whiteway A, Rooney N, Pawade J: Lymphomatoid granulomatosis of the uterine cervix. Pathol Res Pract; 2009;205(5):371-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid granulomatosis of the uterine cervix.
  • Lymphomatoid granulomatosis is an Epstein-Barr virus-driven lymphoproliferative disorder, usually with a prominent pulmonary involvement and occasional extrapulmonary manifestations.
  • Here, we present a case of lymphomatoid granulomatosis confined to the uterine cervix at the initial diagnosis.
  • The disease was preceded by an immunosuppressive condition, namely low-grade lymphoplasmacytic lymphoma treated with chemotherapy.
  • This is the first report of lymphomatoid granulomatosis at this site and emphasizes that it can present at unusual sites, such as the female genital tract in immunosuppressed patients.
  • [MeSH-major] Immunocompromised Host. Lymphomatoid Granulomatosis / immunology. Neoplasms, Second Primary / immunology. Uterine Cervical Neoplasms / immunology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147299.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epstein-Barr virus encoded RNA 2; 0 / RNA, Viral
  •  go-up   go-down


82. Kelly SA, Nehrenberg DL, Peirce JL, Hua K, Steffy BM, Wiltshire T, Pardo-Manuel de Villena F, Garland T Jr, Pomp D: Genetic architecture of voluntary exercise in an advanced intercross line of mice. Physiol Genomics; 2010 Jul 7;42(2):190-200
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our focus was to identify the locations and effects of quantitative trait loci (QTL) controlling genetic predisposition for exercise-related traits, utilizing a large advanced intercross line (AIL) of mice.
  • This AIL (G(4)) population originated from a reciprocal cross between mice with genetic propensity for increased voluntary exercise [high-runner (HR) line, selectively bred for increased wheel running] and the inbred strain C57BL/6J.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neural Transm (Vienna). 2006 Dec;113(12):1921-5 [16736243.001]
  • [Cites] Med Sci Sports Exerc. 2007 Aug;39(8):1423-34 [17762377.001]
  • [Cites] PLoS One. 2007;2(10):e1036 [17940600.001]
  • [Cites] Eur J Hum Genet. 2007 Dec;15(12):1252-9 [17700629.001]
  • [Cites] Physiol Genomics. 2008 Feb 19;32(3):401-8 [18171721.001]
  • [Cites] J Appl Physiol (1985). 2008 Apr;104(4):1243-5 [18048588.001]
  • [Cites] J Appl Physiol (1985). 2008 Apr;104(4):1249 [18385304.001]
  • [Cites] PLoS One. 2008;3(4):e1977 [18431467.001]
  • [Cites] Int J Biol Sci. 2008;4(3):126-32 [18449357.001]
  • [Cites] J Hered. 2008 Jul-Aug;99(4):349-54 [18310069.001]
  • [Cites] Int J Obes (Lond). 2008 Aug;32(8):1256-63 [18504442.001]
  • [Cites] J Hered. 2008 Nov-Dec;99(6):679-87 [18544554.001]
  • [Cites] Med Sci Sports Exerc. 2009 Jan;41(1):35-73 [19123262.001]
  • [Cites] Curr Protoc Hum Genet. 2009 Jan;Chapter 2:Unit 2.12 [19170031.001]
  • [Cites] Br J Sports Med. 2009 Feb;43(2):80-1 [18927165.001]
  • [Cites] Genes Brain Behav. 2009 Feb;8(1):13-22 [18721260.001]
  • [Cites] Mamm Genome. 2009 Apr;20(4):224-35 [19306044.001]
  • [Cites] Genet Res (Camb). 2009 Apr;91(2):85-99 [19393125.001]
  • [Cites] Obesity (Silver Spring). 2009 Jul;17(7):1402-9 [19282822.001]
  • [Cites] BMC Genet. 2009;10:40 [19638241.001]
  • [Cites] Science. 2000 Apr 7;288(5463):100-6 [10753108.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Jul;279(1):R1-8 [10896857.001]
  • [Cites] Lab Anim (NY). 2001 Jul-Aug;30(7):44-52 [11469113.001]
  • [Cites] Genetics. 2001 Sep;159(1):371-87 [11560912.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] Obes Rev. 2002 Feb;3(1):5-8 [12119660.001]
  • [Cites] Evolution. 2002 Jun;56(6):1267-75 [12144025.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3456S-3464S [12421870.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] Med Sci Sports Exerc. 2003 Aug;35(8):1355-9 [12900690.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2003 Aug 22;52(33):785-8 [12931076.001]
  • [Cites] Genetics. 2009 Aug;182(4):1263-77 [19474203.001]
  • [Cites] Genetics. 2009 Aug;182(4):1335-44 [19535546.001]
  • [Cites] Nat Methods. 2009 Sep;6(9):663-6 [19668205.001]
  • [Cites] Physiol Genomics. 2009 Sep 9;39(1):47-55 [19567786.001]
  • [Cites] Physiol Biochem Zool. 2009 Nov-Dec;82(6):662-79 [19799520.001]
  • [Cites] J Hered. 2010 Jan-Feb;101(1):42-53 [19666993.001]
  • [Cites] J Appl Physiol (1985). 2004 Jan;96(1):3-10 [14660491.001]
  • [Cites] Mamm Genome. 2003 Oct;14(10):692-702 [14694905.001]
  • [Cites] Mamm Genome. 2003 Nov;14(11):733-47 [14722723.001]
  • [Cites] Science. 2004 Apr 16;304(5669):445-8 [15031436.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1197-202 [15489855.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1133-7 [15514660.001]
  • [Cites] Am J Physiol. 1994 Oct;267(4 Pt 2):R1098-108 [7943421.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • [Cites] Behav Genet. 1997 May;27(3):201-10 [9210791.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):19-24 [9425894.001]
  • [Cites] Behav Genet. 1998 May;28(3):227-37 [9670598.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] J Comp Physiol Psychol. 1964 Oct;58:159-63 [14215383.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):345-52 [15549097.001]
  • [Cites] Physiol Genomics. 2004 Nov 17;19(3):270-6 [15383638.001]
  • [Cites] Genetics. 2005 Feb;169(2):855-62 [15371360.001]
  • [Cites] Lancet. 2005 Apr 9-15;365(9467):1333-46 [15823385.001]
  • [Cites] Mamm Genome. 2006 Feb;17(2):111-8 [16465591.001]
  • [Cites] Behav Genet. 2006 Mar;36(2):238-47 [16502139.001]
  • [Cites] J Exp Biol. 2006 Jun;209(Pt 12):2344-61 [16731811.001]
  • [Cites] Genetics. 2006 Sep;174(1):481-9 [16783000.001]
  • [Cites] Obesity (Silver Spring). 2006 Sep;14(9):1596-604 [17030971.001]
  • [Cites] Physiol Genomics. 2010 Jan 8;40(2):111-20 [19903762.001]
  • [Cites] J Exp Biol. 2010 Feb 1;213(3):510-9 [20086137.001]
  • [Cites] PLoS One. 2006;1:e22 [17183649.001]
  • (PMID = 20388837.001).
  • [ISSN] 1531-2267
  • [Journal-full-title] Physiological genomics
  • [ISO-abbreviation] Physiol. Genomics
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NIGMS NIH HHS / GM / GM-076468; United States / NIMH NIH HHS / MH / 5T32 MH 075854-04; United States / NIDDK NIH HHS / DK / DK-056350; United States / NIDDK NIH HHS / DK / DK-076050
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3032284
  •  go-up   go-down


83. Yu X, Teng H, Marques A, Ashgari F, Ibrahim SM: High resolution mapping of Cia3: a common arthritis quantitative trait loci in different species. J Immunol; 2009 Mar 1;182(5):3016-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major CIA clinical traits were evaluated in both (DBA/1xFVB/N) F(2) and advanced intercross line (AIL) mice; QTLs were confirmed and refined in AIL.
  • We identified six suggestive QTLs controlling CIA clinical traits in the F(2) progeny; one of these was confirmed and refined in AIL.
  • [MeSH-minor] Age of Onset. Animals. Arthritis, Rheumatoid / diagnosis. Arthritis, Rheumatoid / genetics. Arthritis, Rheumatoid / immunology. Comparative Genomic Hybridization. Crosses, Genetic. Gene Expression Profiling. Genetic Linkage / immunology. Genetic Markers / immunology. Genetic Predisposition to Disease. Humans. Mice. Mice, Inbred DBA. Polymorphism, Genetic / immunology. Rats. Severity of Illness Index

  • Genetic Alliance. consumer health - Arthritis.
  • COS Scholar Universe. author profiles.
  • GeneWeaver. GeneWeaver .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19234197.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


84. Ghebremicael SB, Hasenstein JR, Lamont SJ: Association of interleukin-10 cluster genes and Salmonella response in the chicken. Poult Sci; 2008 Jan;87(1):22-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four genes in the IL10 cluster [polymeric immunoglobulin receptor (PIGR), interleukin 10 (IL10), map kinase-activated protein kinase 2 (MAPKAPK2), and ligatin (LGTN)] plus dual-specificity tyrosine-(Y)-phosphorylation regulated kinase1A (DYRK1A) were investigated using the F(8) generation of 2 related advanced intercross lines (AIL).
  • The AIL were generated by crossing outbred broilers with dams of 2 highly inbred lines (Leghorn and Fayoumi).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079445.001).
  • [ISSN] 0032-5791
  • [Journal-full-title] Poultry science
  • [ISO-abbreviation] Poult. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / ligatin; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA; EC 2.7.1.- / Dyrk kinase; EC 2.7.1.- / MAP-kinase-activated kinase 2; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


85. Ramírez RE, Torres-González LC, Hernández A, García A, Sánchez EM: Conductivity and viscosity behavior of asymmetric phosphonium iodides. J Phys Chem B; 2010 Apr 1;114(12):4271-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We plotted the conductivity and viscosity data of APIs according to Walden's rule and found that they can be classified as an associated ionic liquid (AIL), an intermediate between a true ionic liquid and a molecular species.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205443.001).
  • [ISSN] 1520-5207
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Kot B, Piechota M, Jakubczak A: Analysis of occurrence of virulence genes among Yersinia enterocolitica isolates belonging to different biotypes and serotypes. Pol J Vet Sci; 2010;13(1):13-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The strains of genotype ystA+ail+myfA+yadA+ predominated in biotype 4 (serotype O:3).
  • The strains of biotype 2 (serotype O:9) represented genotype ystA+ail+myfA+, and the plasmid yadA gene was detected in some of them.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077426.001).
  • [ISSN] 1505-1773
  • [Journal-full-title] Polish journal of veterinary sciences
  • [ISO-abbreviation] Pol J Vet Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


87. Yu X, Bauer K, Wernhoff P, Koczan D, Möller S, Thiesen HJ, Ibrahim SM: Fine mapping of collagen-induced arthritis quantitative trait loci in an advanced intercross line. J Immunol; 2006 Nov 15;177(10):7042-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The generation of advanced intercross lines (AIL) is a powerful approach for high-resolution fine mapping of quantitative trait loci (QTLs), because they accumulate much more recombination events compared with conventional F2 intercross and N2 backcross.
  • Therefore, in this study, we produced an AIL to fine map collagen-induced arthritis (CIA) QTLs using comparatively limited resources.
  • We used only 308 (DBA/1 x FVB/N)F11/12 AIL mice to refine QTLs controlling the severity and onset of arthritis as well as the Ab response and T cell subset in CIA, namely Cia2, Cia27, and Trmq3.
  • [MeSH-major] Arthritis, Experimental / genetics. Chromosome Mapping. Crosses, Genetic. Genetic Predisposition to Disease. Quantitative Trait Loci / genetics
  • [MeSH-minor] Animals. Cattle. Collagen Type II / immunology. Female. Gene Expression Profiling. Haplotypes. Male. Mice. Mice, Inbred DBA. Severity of Illness Index

  • COS Scholar Universe. author profiles.
  • GeneWeaver. GeneWeaver .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082620.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type II
  •  go-up   go-down


88. Cheng R, Lim JE, Samocha KE, Sokoloff G, Abney M, Skol AD, Palmer AA: Genome-wide association studies and the problem of relatedness among advanced intercross lines and other highly recombinant populations. Genetics; 2010 Jul;185(3):1033-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To obtain analogous improvements in mapping resolution in mice, we used a 34th generation advanced intercross line (AIL) derived from two inbred strains (SM/J and LG/J).
  • Using a combination of F(2) and AIL mice derived from the same inbred progenitors, we identified genome-wide significant, subcentimorgan loci that were associated with methamphetamine sensitivity, (e.g., chromosome 18; LOD = 10.5) and non-drug-induced locomotor activity (e.g., chromosome 8; LOD = 18.9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genetics. 1994 Nov;138(3):963-71 [7851788.001]
  • [Cites] Mamm Genome. 2008 Mar;19(3):199-208 [18301946.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):19-24 [9425894.001]
  • [Cites] Genetics. 1964 Dec;50:1319-48 [14239792.001]
  • [Cites] Insect Mol Biol. 2004 Dec;13(6):637-48 [15606812.001]
  • [Cites] Nat Rev Genet. 2005 Apr;6(4):271-86 [15803197.001]
  • [Cites] Nat Genet. 2005 May;37(5):486-94 [15821736.001]
  • [Cites] Genetics. 2005 May;170(1):185-94 [15781707.001]
  • [Cites] Mamm Genome. 2005 May;16(5):291-305 [16104378.001]
  • [Cites] PLoS One. 2008;3(4):e1977 [18431467.001]
  • [Cites] Genetics. 2008 Jun;179(2):1069-78 [18505881.001]
  • [Cites] PLoS Genet. 2008;4(8):e1000149 [18688273.001]
  • [Cites] Genes Brain Behav. 2008 Oct;7(7):720-9 [18518925.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):3016-23 [19234197.001]
  • [Cites] Psychopharmacology (Berl). 2009 May;203(4):703-11 [19050854.001]
  • [Cites] Mamm Genome. 2009 Apr;20(4):224-35 [19306044.001]
  • [Cites] Bioinformatics. 2009 Jun 15;25(12):1561-3 [19359355.001]
  • [Cites] PLoS One. 2009;4(6):e5906 [19526058.001]
  • [Cites] Genetics. 2009 Aug;182(4):1263-77 [19474203.001]
  • [Cites] Anim Genet. 2009 Oct;40(5):743-8 [19466935.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):747-53 [19812666.001]
  • [Cites] Ann Rheum Dis. 2009 Dec;68(12):1925-32 [19066175.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):629-50 [10677322.001]
  • [Cites] Mamm Genome. 2000 Aug;11(8):645-8 [10920233.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12389-90 [11050190.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):641-9 [11195461.001]
  • [Cites] Am J Hum Genet. 2001 Nov;69(5):1146-8 [11590549.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3317-24 [12810665.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1654-64 [12805272.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1366-73 [15240732.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1197-202 [15489855.001]
  • [Cites] Ann Hum Genet. 1981 Jul;45(Pt 3):299-305 [7305283.001]
  • [Cites] Mamm Genome. 2005 May;16(5):306-18 [16104379.001]
  • [Cites] Genet Sel Evol. 2005 Mar-Apr;37(2):215-28 [16194525.001]
  • [Cites] PLoS Genet. 2005 Sep;1(3):e32 [16151517.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4419-30 [16547280.001]
  • [Cites] Neuropsychopharmacology. 2006 May;31(5):1056-63 [16237383.001]
  • [Cites] J Immunol. 2006 May 15;176(10):6055-64 [16670314.001]
  • [Cites] Heredity (Edinb). 1992 Oct;69(4):315-24 [16718932.001]
  • [Cites] Mamm Genome. 2006 Jun;17(6):584-97 [16783640.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):879-87 [16832355.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7042-9 [17082620.001]
  • [Cites] Nat Rev Genet. 2007 Jan;8(1):58-69 [17173058.001]
  • [Cites] PLoS Biol. 2006 Nov;4(12):e395 [17105354.001]
  • [Cites] Genetics. 2007 May;176(1):645-57 [17339203.001]
  • [Cites] Genetics. 2007 Jun;176(2):1261-81 [17435224.001]
  • [Cites] PLoS Genet. 2007 Aug;3(8):e144 [17722986.001]
  • [Cites] Genetics. 2007 Sep;177(1):577-85 [17660554.001]
  • [Cites] BMC Genet. 2007;8:66 [17908314.001]
  • [Cites] Neurosci Biobehav Rev. 2008;32(4):707-59 [18207241.001]
  • [Cites] Genetics. 1995 Nov;141(3):1199-207 [8582624.001]
  • (PMID = 20439773.001).
  • [ISSN] 1943-2631
  • [Journal-full-title] Genetics
  • [ISO-abbreviation] Genetics
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH020065; United States / NIMH NIH HHS / MH / T32 MH020065; United States / NIDA NIH HHS / DA / DA024845; United States / NIMH NIH HHS / MH / R01 MH079103; United States / NIDA NIH HHS / DA / R21 DA024845; United States / NHGRI NIH HHS / HG / R01 HG002899
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2907190
  •  go-up   go-down


89. Jennen DG, Vereijken AL, Bovenhuis H, Crooijmans RM, van der Poel JJ, Groenen MA: Confirmation of quantitative trait loci affecting fatness in chickens. Genet Sel Evol; 2005 Mar-Apr;37(2):215-28
SciCrunch. Animal Quantitative Trait Locus Database: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report we describe the analysis of an advanced intercross line (AIL) to confirm the quantitative trait locus (QTL) regions found for fatness traits in a previous study.
  • The AIL was created by random intercrossing in each generation from generation 2 (G(2)) onwards until generation 9 (G(9)) was reached.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194525.001).
  • [ISSN] 0999-193X
  • [Journal-full-title] Genetics, selection, evolution : GSE
  • [ISO-abbreviation] Genet. Sel. Evol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Other-IDs] NLM/ PMC2697231
  •  go-up   go-down


90. Bonardi S, Paris A, Bassi L, Salmi F, Bacci C, Riboldi E, Boni E, D'Incau M, Tagliabue S, Brindani F: Detection, semiquantitative enumeration, and antimicrobial susceptibility of Yersinia enterocolitica in pork and chicken meats in Italy. J Food Prot; 2010 Oct;73(10):1785-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All isolates were tested for yadA, ail, inv, ystA, and ystB virulence sequences.
  • The yadA gene was detected in two strains (3.7%) isolated from chicken samples: one Y. enterocolitica 2/O:9 yadA+ ail+ ystA+, and one Y. enterocolitica 1A/O:7,8-8-8,19 yadA+ inv+ ystB+.
  • Two (3.7%) 2/O:9 strains, isolated from pork products, were ail+ ystA+.

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067665.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


91. Marta M, Stridh P, Becanovic K, Gillett A, Ockinger J, Lorentzen JC, Jagodic M, Olsson T: Multiple loci comprising immune-related genes regulate experimental neuroinflammation. Genes Immun; 2010 Jan;11(1):21-36
SciCrunch. RGD: Data: Animal Model .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-resolution linkage analysis in an advanced intercross line (AIL) revealed four quantitative trait loci (QTLs), Eae24-Eae27.
  • The smallest congenic fragment, which carries Eae25 alone, influenced both susceptibility and severity, and protected from the chronic phase of disease.
  • These results support the multiple QTLs identified in the AIL.
  • [MeSH-major] Encephalomyelitis, Autoimmune, Experimental / genetics. Genetic Predisposition to Disease / genetics. Immunity, Humoral / genetics. Quantitative Trait Loci / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675581.001).
  • [ISSN] 1476-5470
  • [Journal-full-title] Genes and immunity
  • [ISO-abbreviation] Genes Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Mog protein, rat; 0 / Myelin Proteins; 0 / Myelin-Associated Glycoprotein; 0 / Myelin-Oligodendrocyte Glycoprotein
  •  go-up   go-down


92. Bhaduri S, Wesley IV, Bush EJ: Prevalence of pathogenic Yersinia enterocolitica strains in pigs in the United States. Appl Environ Microbiol; 2005 Nov;71(11):7117-21
MedlinePlus Health Information. consumer health - Bowel Movement.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of ail-positive Y. enterocolitica was determined in samples using both a fluorogenic 5' nuclease PCR assay and a culture method.
  • Forty-one of 77 premises (53.25%) contained at least one fecal sample positive for the ail sequence.
  • Among 77 premises, the PCR assay revealed a significantly (P < 0.05) higher percentage (46.75%, n = 36 sites) of samples positive for the pathogen (ail sequence) than the culture method (22.08%, n = 17 sites).
  • [MeSH-major] Bacterial Proteins / genetics. Disease Reservoirs. Feces / microbiology. Swine / microbiology. Yersinia enterocolitica / classification. Yersinia enterocolitica / pathogenicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):3750-5 [10966386.001]
  • [Cites] J Food Prot. 2001 Mar;64(3):355-60 [11252479.001]
  • [Cites] J Food Prot. 2001 Sep;64(9):1352-61 [11563512.001]
  • [Cites] Mol Cell Probes. 2003 Apr-Jun;17(2-3):99-105 [12788031.001]
  • [Cites] Emerg Infect Dis. 2003 Aug;9(8):1007-9 [12967503.001]
  • [Cites] Vet Microbiol. 1983 Oct;8(5):469-83 [6649406.001]
  • [Cites] Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25 [10511517.001]
  • [Cites] N Engl J Med. 1990 Apr 5;322(14):984-7 [2314448.001]
  • [Cites] Appl Environ Microbiol. 1997 May;63(5):1657-60 [9143098.001]
  • [Cites] Appl Environ Microbiol. 1997 Dec;63(12):4952-5 [9406416.001]
  • [Cites] Mol Cell Probes. 1998 Apr;12(2):79-83 [9633042.001]
  • [Cites] J Food Prot. 1998 Jun;61(6):677-82 [9709248.001]
  • [Cites] Can J Vet Res. 1999 Apr;63(2):96-100 [10369565.001]
  • [Cites] Appl Environ Microbiol. 1988 Apr;54(4):851-4 [3377499.001]
  • (PMID = 16269749.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media; 0 / DNA, Bacterial; EC 2.7.7.- / Taq Polymerase
  • [Other-IDs] NLM/ PMC1287643
  •  go-up   go-down


93. Warolin C: [The opiate pharmacopeia in France from its origins to the 19th century]. Rev Hist Pharm (Paris); 2010 Apr;58(365):81-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sydenham's laudanum (1683) was adopted by ail the pharmacopeias.
  • Seguin, but above ail the German pharmacist Sertürner (in 1805 and 1817) isolated morphine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20533811.001).
  • [ISSN] 0035-2349
  • [Journal-full-title] Revue d'histoire de la pharmacie
  • [ISO-abbreviation] Rev Hist Pharm (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 8008-60-4 / Opium
  •  go-up   go-down


94. Fredriksson-Ahomaa M, Wacheck S, Koenig M, Stolle A, Stephan R: Prevalence of pathogenic Yersinia enterocolitica and Yersinia pseudotuberculosis in wild boars in Switzerland. Int J Food Microbiol; 2009 Nov 15;135(3):199-202
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ail-positive Yersiniaenterocolitica and inv-positive Yersiniapseudotuberculosis were detected in 35 and 20% of the animals, respectively.
  • Isolation rate of enteropathogenic Yersinia was low; ail-positive Y. enterocolitica and inv-positive Y. pseudotuberculosis were found in 9 and 3% of the animals, respectively.

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723600.001).
  • [ISSN] 1879-3460
  • [Journal-full-title] International journal of food microbiology
  • [ISO-abbreviation] Int. J. Food Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / DNA, Bacterial
  •  go-up   go-down


95. Middleton B: Achieving U.S. Health information technology adoption: the need for a third hand. Health Aff (Millwood); 2005 Sep-Oct;24(5):1269-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although adoption of HIT will not cure all that ails health care, it is an important step toward transformation of the U.S. health care delivery system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162572.001).
  • [ISSN] 0278-2715
  • [Journal-full-title] Health affairs (Project Hope)
  • [ISO-abbreviation] Health Aff (Millwood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Zheng H, Sun Y, Mao Z, Jiang B: Investigation of virulence genes in clinical isolates of Yersinia enterocolitica. FEMS Immunol Med Microbiol; 2008 Aug;53(3):368-74
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Then, all isolates of pathogenic Y. enterocolitica cultured from the culture method were examined for virulence genes (inv, ail, ystA, ystB, ystC, yadA, virF) by PCR and for the presence of plasmid by four phenotypic tests.
  • The positive rate of virulence genes tested in 160 isolates was inv (100%), ail (94%), ystA (93%), ystB (7.5%), ystC (5%), yadA (89%) and virF (82%) while the phenotypic test included autoagglutination (87%), binding of crystal violet (89%), calcium-dependent growth (74%) and Congo red absorption (78%), respectively.

  • MedlinePlus Health Information. consumer health - Diarrhea.
  • Hazardous Substances Data Bank. Gentian Violet .
  • Hazardous Substances Data Bank. C.I. DIRECT RED 28 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18557936.001).
  • [ISSN] 0928-8244
  • [Journal-full-title] FEMS immunology and medical microbiology
  • [ISO-abbreviation] FEMS Immunol. Med. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA, Bacterial; 0 / Virulence Factors; 3U05FHG59S / Congo Red; J4Z741D6O5 / Gentian Violet; SY7Q814VUP / Calcium
  •  go-up   go-down


97. Nakagame S, Chandra RP, Saddler JN: The effect of isolated lignins, obtained from a range of pretreated lignocellulosic substrates, on enzymatic hydrolysis. Biotechnol Bioeng; 2010 Apr 1;105(5):871-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lower yields of acid insoluble lignin (AIL) obtained from the corn stover when using the PTL method indicated that the lignin from the corn stover had a higher hydrophilicity than did the lignin from the poplar and lodgepole pine.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley Periodicals, Inc.
  • (PMID = 19998278.001).
  • [ISSN] 1097-0290
  • [Journal-full-title] Biotechnology and bioengineering
  • [ISO-abbreviation] Biotechnol. Bioeng.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbohydrates; 0 / Proteins; 11132-73-3 / lignocellulose; 9004-34-6 / Cellulose; 9005-53-2 / Lignin
  •  go-up   go-down


98. Gu L, Wang H, Zhu FC, Shi ZY, Zeng XY, Tan ZY, Xiao YC, Qiu HY, Wang X, Jin D, Cui ZG, Wang B, Kan B, Wang XS, Jing HQ, Xu JG: [Study on the distribution of Yersinia enterocolitica in Nantong, Jinagsu Province]. Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Oct;26(10):786-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The combined isolation rate of Yersinia enterocolitica from livestock and poultry was 31.06% and the gene distribution characters were: 39.57% of them were ail-, ystA- , ystB-, yadA- , virF-; 60.43% were ail- , ystA- , ystB + , yadA- , virF- respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536305.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Virulence Factors
  •  go-up   go-down


99. Lambertz ST, Nilsson C, Hallanvuo S, Lindblad M: Real-time PCR method for detection of pathogenic Yersinia enterocolitica in food. Appl Environ Microbiol; 2008 Oct;74(19):6060-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The selected primer-probe set was designed to use a 163-bp amplicon from the chromosomally located gene ail (attachment and invasion locus).
  • In addition, the method was tested on naturally contaminated food; in all, 18 out of 125 samples were positive for the ail gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):3750-5 [10966386.001]
  • [Cites] Int J Food Microbiol. 2008 Mar 31;123(1-2):25-31 [18206260.001]
  • [Cites] Acta Microbiol Pol. 2001;50(1):19-25 [11518390.001]
  • [Cites] J Food Prot. 2001 Sep;64(9):1352-61 [11563512.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1383-90 [12620820.001]
  • [Cites] Int J Food Microbiol. 2003 May 25;83(1):39-48 [12672591.001]
  • [Cites] Clin Microbiol Rev. 2003 Apr;16(2):220-9 [12692095.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5835 [14662997.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):1863-8 [15131141.001]
  • [Cites] Appl Environ Microbiol. 2004 Jun;70(6):3588-92 [15184161.001]
  • [Cites] J Clin Microbiol. 1986 Jul;24(1):116-20 [3722357.001]
  • [Cites] Infect Immun. 1989 Jan;57(1):121-31 [2642465.001]
  • [Cites] Appl Environ Microbiol. 1991 Feb;57(2):389-94 [2014988.001]
  • [Cites] Int J Food Microbiol. 1991 Jan;12(1):53-65 [2018706.001]
  • [Cites] J Bacteriol. 1992 Feb;174(4):1360-9 [1370953.001]
  • [Cites] Appl Environ Microbiol. 1993 Sep;59(9):2938-44 [8215366.001]
  • [Cites] Appl Environ Microbiol. 1997 Dec;63(12):4952-5 [9406416.001]
  • [Cites] Appl Environ Microbiol. 1998 May;64(5):1812-5 [9572955.001]
  • [Cites] Int J Food Microbiol. 1998 Dec 8;45(2):93-105 [9924940.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):7046-52 [15574899.001]
  • [Cites] Int J Food Microbiol. 2005 Nov 15;105(1):71-82 [16085330.001]
  • [Cites] J Food Prot. 2006 Aug;69(8):1983-5 [16924928.001]
  • [Cites] J Food Prot. 2007 Feb;70(2):335-40 [17340866.001]
  • [Cites] Appl Environ Microbiol. 2007 Mar;73(6):1892-8 [17259359.001]
  • [Cites] Appl Environ Microbiol. 2000 Sep;66(9):4131-5 [10966441.001]
  • (PMID = 18708521.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ail protein, Yersinia enterocolitica; 0 / Bacterial Outer Membrane Proteins; 0 / DNA Primers; 0 / DNA, Bacterial
  • [Other-IDs] NLM/ PMC2565965
  •  go-up   go-down


100. Martínez PO, Fredriksson-Ahomaa M, Sokolova Y, Roasto M, Berzins A, Korkeala H: Prevalence of enteropathogenic Yersinia in Estonian, Latvian, and Russian (Leningrad region) pigs. Foodborne Pathog Dis; 2009 Jul-Aug;6(6):719-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathogenic Y. enterocolitica and Y. pseudotuberculosis were identified by PCR targeting the chromosomal genes ail and inv, respectively.
  • The prevalence of ail-positive Y. enterocolitica was 89% in Estonia, 64% in Latvia, and 34% in Russia, with 81% of ail-positive samples being virF-positive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19580449.001).
  • [ISSN] 1556-7125
  • [Journal-full-title] Foodborne pathogens and disease
  • [ISO-abbreviation] Foodborne Pathog. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement